1. Introduction {#sec1-marinedrugs-18-00005}
===============

The aim of the present review is to consolidate 2014--2015 *preclinical* marine pharmacology, with a format similar to the previous nine reviews of this series, which cover the period 1998--2013 \[[@B1-marinedrugs-18-00005],[@B2-marinedrugs-18-00005],[@B3-marinedrugs-18-00005],[@B4-marinedrugs-18-00005],[@B5-marinedrugs-18-00005],[@B6-marinedrugs-18-00005],[@B7-marinedrugs-18-00005],[@B8-marinedrugs-18-00005],[@B9-marinedrugs-18-00005]\]. The peer-reviewed articles were retrieved from searches in the following databases: MarinLit, PubMed, Chemical Abstracts^®^, ISI Web of Knowledge, and Google Scholar. As in our previous work, we have limited our review to include bioactivity and/or pharmacology of structurally characterized marine chemicals, which we have classified using a modification of Schmitz's chemical classification \[[@B10-marinedrugs-18-00005]\] into six major chemical classes, namely, polyketides, terpenes, peptides, alkaloids, shikimates, and sugars. The preclinical antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic pharmacology of marine chemicals is reported in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, with the structures shown in [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}. Marine compounds that affected the immune and nervous systems, with antidiabetic and anti-inflammatory effects, are exhibited in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"}, with their respective structures consolidated in [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}. Finally, marine compounds affecting a variety of cellular and molecular targets are noted in [Table 3](#marinedrugs-18-00005-t003){ref-type="table"}, and their structures are shown in [Figure 3](#marinedrugs-18-00005-f003){ref-type="fig"}.

Several publications during 2014--2015 reported on several marine extracts or structurally uncharacterized compounds, with novel *preclinical* and/or *clinical* pharmacology: in vitro phenotype-guided the discovery of natural products using cytological profiling to predict modes of action of bioactive constituents in extracts \[[@B11-marinedrugs-18-00005]\]; Colombian and Brazilian marine organisms as source of *antibacterial* extracts with bacterial quorum sensing inhibitory activity \[[@B12-marinedrugs-18-00005]\]; a first report describing antimicrobial activity in extracts from cultivable fungi associated with Antarctic marine sponges \[[@B13-marinedrugs-18-00005]\]; an extensive study on the antimicrobial activity of crude extracts from several species of red algae from Madagascar \[[@B14-marinedrugs-18-00005]\]; bioactive compounds along with a purified macrolactin with broad spectrum antibacterial activity in crude extracts from *B. subtilis* MTCC10403 associated with the Indian brown seaweed *A. longifolius* \[[@B15-marinedrugs-18-00005]\]; potential β-lactamase inhibitory activity in a Bay of Bengal marine *Streptomyces* sp. PM49 with antibacterial properties on multidrug-resistant pathogens \[[@B16-marinedrugs-18-00005]\]; in vitro *anti-inflammatory* activity of an extract and individual components in the spiny seastar *M. glacialis* that inhibited "different levels of the inflammation pathway" \[[@B17-marinedrugs-18-00005]\]; in vitro anti-inflammatory activity of several galactolipids isolated from methanol extracts of cultivated red alga *Chondrus crispus* that were proposed "to counter inflammation associated with NO-mediated disorders" \[[@B18-marinedrugs-18-00005]\]; in vitro immunomodulatory activity of an extract of the Bohai sea ascidian *Styela clava* that exhibited proliferative activity and promoted nitric oxide (NO) release from mouse lymphocytes and macrophages \[[@B19-marinedrugs-18-00005]\]; in vivo anti-inflammatory activity of a new nucleoside, dragmacidoside isolated from an extract of a marine Red sea sponge *Dragmacidon coccinea* \[[@B20-marinedrugs-18-00005]\]; in vivo anti-inflammatory and analgesic activities of an organic extract and its semipurified fractions from the Tunisian gorgonian *Eunicella singularis*, which suggested that "components of the active fraction can be used to treat various anti-inflammatory diseases" \[[@B21-marinedrugs-18-00005]\]; in vitro anti-inflammatory activity of 30 compounds in a methanol extract of the digestive gland of the Mediterranean sea hare *Aplysia depilans,* which could provide "beneficial anti-inflammatory effects" \[[@B22-marinedrugs-18-00005]\]; and, as part of anti-obesity nutraceuticals research, the anti-adipogenic activity of phlorotannins isolated from the edible brown alga *Ecklonia cava* were reported to be a "promising source for utilization against obesity and related complications" \[[@B23-marinedrugs-18-00005]\].

2. Marine Compounds with Antibacterial, Antifungal, Antiprotozoal, Antituberculosis, Antiviral, and Anthelmintic Activities {#sec2-marinedrugs-18-00005}
===========================================================================================================================

[Table 1](#marinedrugs-18-00005-t001){ref-type="table"} presents 2014--2015 preclinical pharmacological research on the antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic activities of marine natural products (**1**--**133**) shown in [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}.

2.1. Antibacterial Activity {#sec2dot1-marinedrugs-18-00005}
---------------------------

During 2014--2015, 48 studies reported *antibacterial* marine natural products (**1**--**64**) isolated from bacteria, fungi, tunicates, sponges, soft corals, sea snakes, fish, and algae; a research enterprise focused on the discovery of novel chemical leads to treat emerging drug-resistant bacterial infections.

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, nine publications reported on the mode of action of marine-derived antibacterial compounds. Rodríguez and colleagues reported on "a practical synthesis of the axinellamines" (**1**, **2**), as well as their broad spectrum Gram-positive and Gram-negative antibacterial activity, probably resulting from "secondary membrane destabilization...consistent with the inhibition of normal septum formation" \[[@B24-marinedrugs-18-00005]\]. Moon and colleagues characterized a new pentacyclic antibiotic, buanmycin (**3**), isolated from a Korean marine *Streptomyces* strain, which was active towards Gram-native *Salmonella enterica* that causes salmonellosis, by inhibiting sortase A, an enzyme involved in bacterial adhesion and proposed as a "promising target for antibiotic discovery" \[[@B25-marinedrugs-18-00005]\]. Wei and colleagues discovered a novel peptide cathelicidin (**4**) from the Chinese sea snake *Hydrophis cyanocinctus* with potent antimicrobial activity against 35 strains of 48 human pathogenic bacteria, probably by a mechanism that involved "disruption of cell membrane and lysis of bacterial cells...resulting in cellular disruption of both Gram-positive and Gram-negative bacteria" \[[@B26-marinedrugs-18-00005]\]. Silva and colleagues demonstrated that the antimicrobial peptide clavanin A (**5**) significantly reduced *E. coli* and *S. aureus*-infected mice mortality with concomitant reduction of proinflammatory cytokines, thus proposing that clavalin A "... will facilitate studies on the development of novel peptide-based strategies for the treatment of infected wounds and sepsis" \[[@B27-marinedrugs-18-00005]\]. Abdelmohsen and colleagues investigated the new sterol gelliusterol E (**6**) from the Red sea sponge *Callyspongia* aff. *implexa* and showed that it inhibited both the primary infection by *Chlamydia trachomatis*, an obligate intracellular Gram-negative bacterium, as well as the production of viable progeny, and thus the developmental cycle of this bacterium \[[@B28-marinedrugs-18-00005]\]. Pieri and colleagues described new ianthelliformisamine B and C (**7, 8**) from the marine sponge *Suberea ianthelliformis* as antibiotic enhancers against resistant Gram-negative bacteria by a mechanism described as "altered proton homeostasis", and thus probably affecting drug transport \[[@B29-marinedrugs-18-00005]\]. Huang and colleagues showed that the antimicrobial peptide pardaxin (**9**) isolated from the Red sea flatfish *Pardachirus marmoratus* protected mice from a lethal dose of methicillin-resistant *Staphylococcus aureus*, while also accelerating wound healing, increasing monocytes' and macrophages' recruitment, as well as expression of vascular endothelial growth factor \[[@B30-marinedrugs-18-00005]\]. Eom and colleagues described the mechanism of antibacterial activity of the phlorotannin phlorofucofuroeckol-A (**10**) isolated from the edible brown alga *Eisenia bicyclis*, which was shown to involve suppression of several *mec* operon genes in methicillin-resistant *Staphylococcus aureus* as well as the production of penicillin-binding protein 2a, considered as the "primary cause of methicillin resistance" \[[@B31-marinedrugs-18-00005]\]. Hassan and colleagues reported a new depsipeptide salinamide F (**11**), isolated from a marine-derived *Streptomyces* sp. strain CNB-091 that was observed to significantly inhibit RNA polymerase (RNAP) from both Gram-positive and Gram-negative bacteria, but "does not interact with the rifampin binding site on RNAP" \[[@B32-marinedrugs-18-00005]\].

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, 53 marine natural products (**12**--**64**), some of them novel, were reported to exhibit antibacterial activity with MICs \<10 μg/mL or 10 μM against several Gram-positive and Gram-negative bacterial strains, although the mechanism of action for these compounds remained undetermined: two antimicrobial peptides, piscidins 3 and 4 (**12, 13**) originally isolated from the fish tilapia *Oreochromis niloticus* \[[@B33-marinedrugs-18-00005]\]; a new bisthiodiketopiperazine adametizine A (**14**), isolated from a marine sponge-derived fungus *Penicillium adametzioides* AS-53 \[[@B34-marinedrugs-18-00005]\]; two dimeric bromopyrrole alkaloids agelamadins A and B (**15, 16**), isolated from the Okinawan marine sponge *Agelas* sp. \[[@B35-marinedrugs-18-00005]\]; a butyrolactone derivative (**17**), isolated from the fermentation broth of a South China sea gorgonian *Muricella abnormalis*-derived *Aspergillus* sp. XS-20090B15 fungus \[[@B36-marinedrugs-18-00005]\]; a meroditerpene aszonapyrone A (**18**), isolated from the Thai marine sponge *Chondrilla asutraliensis*-associated fungus *Neosartorya paulistensis* (KUFC 7897) \[[@B37-marinedrugs-18-00005]\]; a new meroterpenoid, austalide R (**19**), from a fungus *Aspergillus* sp. isolated from the Mediterranean sponge *Tethya aurantium* \[[@B38-marinedrugs-18-00005]\]; a novel citrifelin B (**20**) with a unique tetracyclic framework was characterized from a co-culture of marine-derived fungi *Penicillium citrinum* and *Beauveria felina* \[[@B39-marinedrugs-18-00005]\]; a novel cyclohexadepsipeptide desmethylisaridin C1 (**21**) identified from a marine bryozoan-derived fungus *Beauveria felina* EN-135 \[[@B40-marinedrugs-18-00005]\]; two novel polybrominated diphenyl ethers (**22, 23**), isolated from the cosmopolitan marine sponge *Dysidea* spp. \[[@B41-marinedrugs-18-00005]\]; a new pentacyclic cytochalasin diaporthalasin (**24**), isolated from the marine-derived fungus *Diaporthaceae* sp. PSU-SP2/4 \[[@B42-marinedrugs-18-00005]\]; natural brominated furanones (**25, 26**), isolated from the marine alga *Delisea pulchra* \[[@B43-marinedrugs-18-00005]\]; a novel meroterpenoid aureol B (**27**), isolated from the Micronesian *Dysidea* sp. sponge \[[@B44-marinedrugs-18-00005]\]; a novel meroterpenoid dysidinoid A (**28**), isolated from the South China sea sponge *Dysidea* sp. \[[@B45-marinedrugs-18-00005]\]; a terpenoid fuscoside E peracetate (**29**) and a lipid batyl alcohol (**30**), isolated from the Colombian soft coral *Eunicea* sp. \[[@B46-marinedrugs-18-00005]\]; a new aromatic butyrolactone flavipesin A (**31**), isolated from a marine-derived endophytic fungus *Aspergillus flavipes* \[[@B47-marinedrugs-18-00005]\]; new non-cytotoxic lipopeptides gageopeptides A--D (**32, 33, 34, 35**) \[[@B48-marinedrugs-18-00005]\] and gageotetrins A--C (**36, 37, 38**) \[[@B49-marinedrugs-18-00005]\], isolated from a Korean marine-derived *Bacillus subtilis* strain 109GGC020; a new cyclic depsipeptide hormaomycin B (**39**), isolated from a Korean marine mudflat-derived actinomycete *Streptomyces* sp. strain SNM55 \[[@B50-marinedrugs-18-00005]\]; a new glycolipid ieodoglucomide C (**40**) from the Korean marine-derived bacterium *Bacillus licheniformis* strain 09IDYM23 \[[@B51-marinedrugs-18-00005]\]; a new polycyclic tetramic acid macrolactam isoikarugamycin (**41**) from Equatorial Guinean *Streptomyces zhaozhouensis* strain CA-185989 \[[@B52-marinedrugs-18-00005]\]; a bromopyrrole alkaloid keramadine (**42**), isolated from the Okinawan marine sponge *Agelas* sp. \[[@B53-marinedrugs-18-00005]\]; "unprecedented" 9,11 secosterols with "the 2-ene-1,4-dione moiety" (**43, 44**) from the Korean marine sponge *Ircinia* sp. \[[@B54-marinedrugs-18-00005],[@B55-marinedrugs-18-00005]\]; two polybrominated diphenyl ethers (**45, 46**) from the Papuan New Guinea marine sponge *Lendenfeldia dendyi* and the soft coral *Sinularia dura* \[[@B56-marinedrugs-18-00005]\]; a novel polyketide lindgomycin (**47**) from the Baltic sea and Arctic Lindgomycetaceae family marine fungal strains KF970 and LF327 \[[@B57-marinedrugs-18-00005]\]; a novel cycloheptadepsipeptide marfomycin D (**48**)**,** isolated from a South China marine *Streptomyces drozdowiczii* SCSIO 10141 \[[@B58-marinedrugs-18-00005]\]; an glycohexadepsipeptide-polyketide mollemycin A (**49**) from an Australian marine-derived *Streptomyces* sp. strain CMB-M0244 \[[@B59-marinedrugs-18-00005]\]; a novel laurene-type sesquiterpene neolaurene (**50**) from a Bornean marine alga *Laurencia nangii* \[[@B60-marinedrugs-18-00005]\]; a new polyketide and ambuic acid analogue penicyclone A (**51**), isolated form an extract from a deep-sea derived fungus *Penicillium* sp. F23-2 \[[@B61-marinedrugs-18-00005]\]; a new phenolic enamide (**52**), characterized from the Chinese marine alga *Codium fragile*-derived endophytic fungus *Penicillium oxalicum* strain EN-290 \[[@B62-marinedrugs-18-00005]\]; a novel meroterpenoid puupehenol (**53**), isolated from a Hawaiian sponge *Dactylospongia* sp. \[[@B63-marinedrugs-18-00005]\]; a new scalarane sesterpene phyllospongin E (**54**), isolated from the Egyptian Red sea sponge *Phyllospongia lamellosa* \[[@B64-marinedrugs-18-00005]\]; two new rare pyrane-based cembranoids sarcotrocheliol acetate (**55**) and sarcotrocheliol (**56**), isolated from the Red sea soft coral *Sarcophyton trocheliophorum* \[[@B65-marinedrugs-18-00005]\]; a novel depsidone-based analogue spiromastixone J (**57**), isolated from the fermentation broth of a deep-sea *Spiromastix* sp. fungus \[[@B66-marinedrugs-18-00005]\]; a new spirocyclic drimane stachyin B (**58**), identified in the mycelia and culture broth of a North sea *Stachybotrys* sp. fungus strain MF347 \[[@B67-marinedrugs-18-00005]\]; a naphthacene glycoside SF2446A2 (**59**), isolated from a culture of *Streptomyces* sp. strain RV15 derived from the Mediterranean sponge *Dysidea tupha* \[[@B68-marinedrugs-18-00005]\]; three new subergosterones A--C (**60**--**62**), obtained from the South China sea gorgonian coral *Subergorgia rubra* \[[@B69-marinedrugs-18-00005]\]; an amino-polyketide vitroprocine A (**63**), isolated from the marine bacterium *Vibrio* sp. strain QWI-06 \[[@B70-marinedrugs-18-00005]\]; and a new polyacetylene derivative xestospongiamide (**64**), isolated from the Red sea sponge *Xestospongia* sp. \[[@B71-marinedrugs-18-00005]\].

Furthermore, during 2014--2015, several other marine natural products, some of them novel, reported antimicrobial activity in MICs or IC~50~'s ranging from 10 to 50 μg/mL, or 10--50 μM, respectively, and thus, because of their lower antibacterial potency, were *excluded* from [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}: tetracyclic sesterterpenes from a Korean marine sponge *Clathria gombawuiensis* sp. (MIC = 6.25--25 μg/mL) \[[@B129-marinedrugs-18-00005]\]; the antimicrobial peptide isolated from the mucus of the hagfish *Myxine glutinosa* and several structural analogs (MICs = 1.2--50 µM) \[[@B130-marinedrugs-18-00005]\]; bromopyrrole alkaloids agelamadins C--E (IC~50~ = 32 μg/mL) from the Okinawan marine sponge *Agelas* sp. \[[@B131-marinedrugs-18-00005]\]; a new indole diterpenoid from the fungus *Aspergillus flavus* (MIC = 20.5 µM), isolated from the Chinese prawn *Penaeus vannamei* \[[@B132-marinedrugs-18-00005]\]; two new bromopyrrole alkaloids isolated from the Okinawan sponge *Agelas* sp., namely 2-debromomonagelamide U and 2-debromomukanadin G (MIC=32 μg/mL) \[[@B133-marinedrugs-18-00005]\]; seven known and one new sesquiterpene named epoxysubergorgic acid isolated from the Chinese gorgonian coral *S. suberosa* (MIC\>8 μg/mL) \[[@B134-marinedrugs-18-00005]\]; a new bromotyrosine alkaloid aplysamine 8 (MIC=31 μg/mL) from an Australian marine sponge *Pseudoceratina purpurea* \[[@B135-marinedrugs-18-00005]\], alternariol derivatives (MIC = 50 μg/disk) from the endophytic fungus *Alternaria alternata* isolated from the Red sea soft coral *Litophyton arboretum* \[[@B136-marinedrugs-18-00005]\]; new polyketides amphidins C--F (MIC = 16 and 32 μg/mL), isolated from the culture broth of dinoflagellate *Amphidinium* sp. \[[@B137-marinedrugs-18-00005]\]; a new 1-deoxysphingoid, 3-*epi*-xestoaminol C (MIC = 32.6 µM), isolated from the New Zealand brown alga *Xiphophora chondrophylla* \[[@B138-marinedrugs-18-00005]\]; a new cyclic pentapeptide, asperpeptide A (MIC = 12.5 µM), isolated from the gorgonian-derived fungus *Aspergillus* sp. \[[@B139-marinedrugs-18-00005]\]; a nucleoside derivative, kipukasin H (MIC = 12.5 µM), isolated from the fungus *A. versicolor* derived from the Xisha islands, South China sea gorgonian *D. gemmacea* \[[@B140-marinedrugs-18-00005]\]; a new *O*-containing heterocyclic compound named felinone B (MIC = 32 μg/mL) from an extract of *B. feline* EN-135, a fungus isolated from an unidentified marine bryozoan \[[@B141-marinedrugs-18-00005]\]; new xanthone microluside A (MIC = 10--13 µM) from a Red sea marine sponge *S. vagabunda*-derived *Micrococcus* sp. EG45 \[[@B142-marinedrugs-18-00005]\]; a new cyclohexapeptide desotamide B (MIC = 12--16 μg/mL) from a South China sea marine microbe *S. scopuliridis* SCSIO ZJ46 \[[@B143-marinedrugs-18-00005]\]; new linear lipopeptides (MIC = 16 and 32 μg/mL) from a Korean marine *Bacillus subtillis* \[[@B144-marinedrugs-18-00005]\]; a new streptophenazine K (MIC = 14.5--21.6 µM) from bacteria isolated from a Baltic sea sponge *Halichondria panacea* \[[@B145-marinedrugs-18-00005]\]; a novel polyketide amantelide A (MIC = 32 µM) from a Guamanian Oscillatoriales cyanobacterium \[[@B146-marinedrugs-18-00005]\]; a novel echinomycin analog, quinomycin G (MIC = 16--64 μg/mL), isolated from *Streptomyces* sp. LS298 from a Hainan marine sponge *Gelliodes carnosa* \[[@B147-marinedrugs-18-00005]\]; and new cyclic lipopeptides gageopeptins A and B (MIC = 6 and 32 μg/mL) from a marine-derived strain *Bacillus* sp. 109GGC020 \[[@B144-marinedrugs-18-00005]\].

2.2. Antifungal Activity {#sec2dot2-marinedrugs-18-00005}
------------------------

Sixteen studies during 2014--2015 reported on the *antifungal* activity of several marine natural products (**64**--**83**) isolated from marine bacteria, dinoflagellates, sponges, sea cucumbers, and algae, a slight increase from our last review \[[@B9-marinedrugs-18-00005]\] and previous reviews of this marine pharmacology series.

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, three reports described antifungal marine chemicals with novel mechanisms of action. Lee and colleagues investigated the new macrocyclic lactone antifungal bahamaolide A (**65**) isolated from the culture of marine actinomycete *Streptomyces* sp. CNQ343 \[[@B72-marinedrugs-18-00005]\]. Detailed studies determined that the compound inhibited isocitrate lyase (ICL) mRNA expression, suggesting it might be used for treatment of "*C. albicans* infections via inhibition of ICL activity". Sugiyama and colleagues characterized the biological activity of the polyene macrolactam heronamide C (**66**) isolated from a marine-derived *Streptomyces* sp. \[[@B73-marinedrugs-18-00005]\]. The heronamide C was shown to induce abnormal cell wall morphology by "perturbing membrane microdomains". Wyche and colleagues reported a novel marine-derived polyketide forazoline A (**67**) isolated from an *Actinomadura* sp. strain WMMB-499 cultivated from the ascidian *Ecteinascidia turbinata* \[[@B74-marinedrugs-18-00005]\]. Using chemical genomics, the authors proposed forazoline A worked in vivo in mice against the fungus *Candida albicans* by affecting cell membrane integrity by a "novel mechanism of action from known antifungal agents".

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, several marine natural products showed antifungal activity with MICs that were either less than 10 μg/mL, 10 μM, or 10 μg/disk, but no mechanism of action studies were reported in the papers: an alkaloid aaptamine derivative (**68**), isolated from the South China sea sponge *Aaptos aaptos* \[[@B75-marinedrugs-18-00005]\]; a new linear polyketide amphidinin G (**69**), isolated from a Japanese symbiotic marine dinoflagellate *Amphidinium* sp. discovered in a marine flatworm *Amphiscolops* sp. \[[@B76-marinedrugs-18-00005]\]; a new polyketide amphidinol 18 (**70**), isolated from the dinoflagellate *Amphidinium carterae* strain CCMP121 \[[@B77-marinedrugs-18-00005]\]; new crambescin A2 (**71**--**73**), alkaloid homologues from the Bahamian marine sponge *Pseudaxinella reticulata* \[[@B78-marinedrugs-18-00005]\]; two new saponins cousteside C (**74**) and D (**75**), reported from the Egyptian Red sea cucumber *Bohadschia cousteaui* \[[@B79-marinedrugs-18-00005]\]; two new laurane-type sesquiterpenes, laurepoxyene (**76**) and 3β-hydroxyperoxyaplysin (**77**), and a new polyunsaturated fatty acid ethyl ester (**78**), isolated from the Chinese red alga *Laurencia okamurai* \[[@B80-marinedrugs-18-00005],[@B81-marinedrugs-18-00005]\]; a novel dilactone-tethered pseudo-dimeric peptide mohangamide A (**79**), isolated from a Korean marine *Streptomyces* sp. \[[@B82-marinedrugs-18-00005]\]; a novel pleosporallin E (**80**), isolated from a marine fungus *Pleosporales* sp., discovered on the South China sea alga *Enteromorpha clathrata* \[[@B83-marinedrugs-18-00005]\]; a lysophospholipid (**81**), isolated from the South China sea sponge *Spirastrella purpurea* \[[@B84-marinedrugs-18-00005]\]; an acetylenic fatty acid derivative taurospongin A (**82**) from an Okinawan marine sponge SS-1202, family Spongiidae \[[@B85-marinedrugs-18-00005]\], and a new non-sulphated triterpene glycoside variegatuside D (**83**) from the south China sea cucumber *Stichopus variegates* \[[@B86-marinedrugs-18-00005]\]. Mechanism of action studies will be required to characterize the antifungal pharmacology of these marine-derived natural compounds.

In addition, novel structurally-characterized marine molecules with antifungal MICs or IC~50~'s greater than 10 μg/mL, 10 μM, or 10 μg/disk, which have been *excluded* from [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"} because of their weaker bioactivity: a new bromopyrrole alkaloid mukanadine G (IC~50~ = 8--16 μg/mL) isolated from the Okinawan marine sponge *Agelas* sp. \[[@B53-marinedrugs-18-00005]\]; a new C24-acetylenic acid, biemnic acid (MIC = 100 μg/disk) isolated from the Red sea sponge *Biemna ehrenbergi* \[[@B148-marinedrugs-18-00005]\]; two sulfated steroid-aminoacid conjugates isolated from the Irish marine sponge *Polymastia boletiformis* (MIC = 100 μg/disk) against *C. albicans* \[[@B149-marinedrugs-18-00005]\]; two novel lysophospholids from the Guanxi sponge *S. purpurea* (IC~50~ = 16 and 32 μg/mL) \[[@B84-marinedrugs-18-00005]\]; two new bromotyrosine alkaloids, tyrokeradine G and H, isolated from an Okinawan Verongid marine sponge (MIC = 16 and 32 μg/mL) \[[@B150-marinedrugs-18-00005]\]; two highly brominated polyphenols isolated from the Qingdao red alga *S. latiuscula* (MIC = 12.5, 25 μg/mL) \[[@B151-marinedrugs-18-00005]\]; one novel anhydride metabolite, tubingenoic anhydride A (MIC = 330 μM), from the Mediterranean fungus *A. tubingensis* (Strain OY907) \[[@B152-marinedrugs-18-00005]\]; and a novel compound terretrione D (MIC = 32 μg/mL) from a tunicate-derived fungus *Penicillium* sp. CYE-97 \[[@B153-marinedrugs-18-00005]\]. These novel marine compounds may contribute to the antifungal preclinical and clinical pipeline upon further research.

2.3. Antiprotozoal and Antituberculosis Activity {#sec2dot3-marinedrugs-18-00005}
------------------------------------------------

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, during 2014--2015, twenty-four studies contributed to novel findings on *antiprotozoal (antimalarial, antileishmanial, and antitrypanosomal)* and *antituberculosis* pharmacology of structurally characterized marine natural products (**84**--**112**), very similar to our previous 1998--2013 marine pharmacology reviews \[[@B1-marinedrugs-18-00005],[@B2-marinedrugs-18-00005],[@B3-marinedrugs-18-00005],[@B4-marinedrugs-18-00005],[@B5-marinedrugs-18-00005],[@B6-marinedrugs-18-00005],[@B7-marinedrugs-18-00005],[@B8-marinedrugs-18-00005],[@B9-marinedrugs-18-00005]\].

Malaria, a global disease caused by protozoan genus *Plasmodium* (*P. falciparum*, *P. ovale*, *P. vivax* and *P. malariae*), currently affects over 2 billion people worldwide. Contributing to the global search for novel antimalarial drugs, and as presented in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, 11 marine molecules (**84**--**94**) isolated from bacteria, molluscs, sponges, and soft corals were shown during 2014--2015 to possess *antimalarial activity*. Young and colleagues reported a detailed mechanistic study with the marine sesquiterpene isonitrile 7,20-diisocyanoadociane (**84**) originally isolated from the marine sponge *Cymbastela hooperi* \[[@B87-marinedrugs-18-00005]\], demonstrating that it inhibited β-hematin (IC~50~ = 13nM), and thus interfered with the parasite's heme detoxification pathway.

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, potent (IC~50~ \< 2 µM) to moderate (IC~50~ \> 2--10 µM) *antimalarial* activity was reported for several marine natural products (**85**--**94**), although the mechanism of action for these compounds remained undertermined at the time of publication. Cheng and colleagues reported potent antiplasmodial activity in the peptide actinoramide A (**85**) isolated from *Streptomyces* species "in all five (*P. falciparum*) lines retested" \[[@B88-marinedrugs-18-00005]\]. Yang and colleagues discovered that a novel norditerpene diacarperoxide J (**86**) isolated from the South China Sea sponge *Diacarnus megaspinorhabdosa* was a moderate growth inhibitor of *P. falciparum* D6 clone, and observed that the peroxy functional group might be a "potential pharmacophore" \[[@B89-marinedrugs-18-00005]\]. Thao and colleagues characterized cembranoid diterpene laevigatol A (**87**) from several Vietnamese soft corals with potent antimalarial activity against drug sensitive *P. falciparum* strain NF54 \[[@B90-marinedrugs-18-00005]\]. Raju and colleagues showed that the glycohexadepsipeptide-polyketide mollemycin A (**49**) isolated from an Australian marine-derived *Streptomyces* sp. strain CMB-M0244 strongly inhibited drug sensitive *P. falciparum* strain 3D7 and multidrug resistant strain Dd2 \[[@B59-marinedrugs-18-00005]\]. Avilés and colleagues noted that isocyanide amphilectane-type diterpenes monamphilectines B and C (**88, 89**), isolated from the Caribbean sponge *Svenzea flava*, exhibited strong inhibitory activity against *P. falciparum* strain 3D7 \[[@B91-marinedrugs-18-00005]\]. Gros and colleagues observed that among the novel tricyclid alkaloids isolated from the Madagascar marine sponge *Biemna laboutei* netamine K (**90**) exhibited inhibitory activity against several *P. falciparum* strains \[[@B92-marinedrugs-18-00005]\]. White and colleagues reported several novel isocyano/isothiocyanate sesquiterpenes (**91--93**) isolated from the nudibranch *Phyllidia ocellata* that showed strong antiplasmodial activity against drug resistant *P. falciparum* Dd2 and 3D7 strains \[[@B93-marinedrugs-18-00005]\]. Chianese and colleagues assessed antimalarial activity of the novel endoperoxide polyketide (**94**) from the South China sea marine sponge *Plakortis simplex* against the *P. falciparum* chloroquine-sensitive D10 and chloroquine-resistant W2 strains \[[@B94-marinedrugs-18-00005]\].

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, thirteen marine compounds (**95**--**107**) isolated from bacteria, fungi, sponges, and soft corals were reported to possess bioactivity towards the so-called neglected protozoal diseases: leishmaniasis, caused by the genus *Leishmania (L.*); amebiasis, trichomoniasis, as well as African sleeping sickness (caused by *Trypanosoma (T.) brucei rhodesiense* and *T. brucei gambiense*), and American sleeping sickness or Chagas disease (caused by *T. cruzi*).

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, two reports described two *antitrypanosomal* marine chemicals (**95**, **96**) as well as their mechanisms of action. Oli and colleagues examined the mode of action of plakortide E (**95**), isolated from the sponge *Plakortis halichondrioides*, and demonstrated that it inhibited activity of *T. brucei* by a non-competitive, covalent or "mechanisms leading to slow-binding", reversible inhibition of the parasite's enzyme rhodesain \[[@B95-marinedrugs-18-00005]\]. Santos and colleagues extended the pharmacology of guanidine and pyrimidine alkaloids from the Brazilian marine sponge *Monanchora arbuscula*, and reported that batzelladine L (**96**) affected both trypomastigotes of *T. cruzi* and *L. infantum* promastigotes, demonstrating that several mechanisms including altered plasma membrane permeability, mitochondrial membrane depolarization, and increased reactive oxygen species, probably contributing to "parasite cell death" \[[@B96-marinedrugs-18-00005]\].

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, eleven additional marine natural products (**97**--**107**) exhibited *antileishmanial* and *antiprotozoal* activity, although their mechanisms of action remained undetermined. Abdelmohsen and colleagues reported that a new *O*-glycosylated angucycline actinosporin A (**97**), isolated from a culture of *Actinokineospora* sp. strain EG49 cultivated from a Red sea sponge *Spheciospongia vagabunda*, moderately inhibited the growth of *T. brucei brucei* \[[@B97-marinedrugs-18-00005]\]. Thao and colleagues isolated the terpenoid astropectenol A (**98**) from a Vietnamese marine sea star *Astropecten polyacanthus*, and observed significant activity against *T. cruzi* and *T. brucei brucei* \[[@B98-marinedrugs-18-00005]\]. Viegelmann and colleagues identified a new saringosterol derivative (**99**) from the Irish marine sponge *Haliclona simulans*, which demonstrated antitrypanosomal activity against *T. brucei brucei* \[[@B99-marinedrugs-18-00005]\]. Using genome-directed lead discovery, Schulze and colleagues contributed a novel polyene macrolactam lobosamide A (**100**) from a marine actinobacterium *Micronospora* sp. that was highly active towards the parasite *T. brucei brucei,* "likely via a parasite-specific mechanism" that remained undetermined \[[@B100-marinedrugs-18-00005]\]. Thao and colleagues assessed the cembranoid diterpenes lobocrasols A and C (**101, 102**), and crassumols D and E (**104, 105**), isolated from several Vietnamese soft corals, and noted that they displayed potent activity against *L. donovani* amastigotes and *T. brucei rhodesiense,* respectively \[[@B90-marinedrugs-18-00005]\]. Nakashima and colleagues found a new cyclopentadecane antibiotic mangromicin A (**103**) separated from the culture broth of the fungus *Lechevalieria aerocolonigenes* K10-0216 isolated from a Japanese mangrove sediment with potent activity against *T. brucei brucei* strain GUTat 3.1 \[[@B101-marinedrugs-18-00005]\]. Yang and colleagues characterized a new scalarane sesterterpene sesterstamide (**106**) isolated from the Paracel islands marine sponge *Hyrtios* sp. that moderately inhibited *L. donovani* promastigotes \[[@B102-marinedrugs-18-00005]\]. Von Salm and colleagues contributed a novel tricyclic sesquiterpenoid shagene A (**107**) from an "undescribed" soft coral collected from the "Scotia Arc in the Southern Ocean" that was moderately active against *L. donovani* \[[@B103-marinedrugs-18-00005]\].

Drug-resistant strains of the intracellular pathogen *Mycobacterium tuberculosis* have stimulated a search for novel drug leads with novel mechanisms of action, and, as shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, five novel marine natural products (**108**--**112**) isolated from sponges and fungi evidenced promising activity, and thus contributed to the ongoing global search for novel *antituberculosis* agents during 2014--2015.

Arai and colleagues identified a novel aaptamine class alkaloid, 2-methoxy-3-oxoaaptamine (**108**), from a marine sponge *Aaptos* sp. that demonstrated strong inhibitory activity against *M. smegmatis* in "both active growing and dormancy-inducing hypoxic conditions" \[[@B104-marinedrugs-18-00005]\]. Daletos and colleagues isolated cyclic peptides callyaerins A and B (**109, 110**), from the Indonesian sponge *Callyspongia aerizusa*, that demonstrated potent antibacterial activity against *M. tuberculosis*, highlighting the "potential of these compounds as promising anti-TB agents" \[[@B105-marinedrugs-18-00005]\]. Kumar and colleagues established that a new diarylpyrrole alkaloid denigrin C (**111**) from an extract of the Indian marine sponge *Dendrilla nigra* exhibited strong *M. tuberculosis* H~37~Rv activity "with a probable novel mechanism needed for antitubercular drug design..." \[[@B106-marinedrugs-18-00005]\]. Lin and colleagues characterized a racemic, prenylated polyketide dimer, oxazinin A (**112**) from a filamentous fungus isolated from the Papua New Guinea ascidian *Lissoclinum patella*, which showed activity against *M. tuberculosis* with modest activity towards human transient receptor potential channels \[[@B107-marinedrugs-18-00005]\].

2.4. Antiviral Activity {#sec2dot4-marinedrugs-18-00005}
-----------------------

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, twenty-one reports were published during 2014--2015 on the *antiviral* pharmacology of marine natural products (**113**--**132**) against human enterovirus 71, human cytomegalovirus, human immunodeficiency virus type-1 (HIV-1), human herpes simplex virus (HSV), influenza virus, hepatitis B virus, murine norovirus, respiratory syncytial virus (RSV), and sindbis virus.

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, five reports described antiviral marine chemicals and their mechanisms of action. González-Almela and colleagues extended the pharmacology of pateamine A (**113**), isolated from the marine sponge *Mycale* sp. by demonstrating that the compound affected the translation of genomic and subgenomic mRNAs from Sindbis virus, although "subgenomic mRNA translation (was) more resistant to pateamine A inhibition" \[[@B108-marinedrugs-18-00005]\]. León and colleagues identified abyssomicin 2 (**114**) from a marine-derived actinobacterium *Streptomyces* sp. that reactivated human immunodeficiency virus type-1 (HIV-1) by a protein kinase C and histone deacetylase-independent mechanism that "remains to be elucidated" \[[@B109-marinedrugs-18-00005]\]. Karadeniz and colleagues reported that the anti-HIV activity of the phlorotannin derivative 8,4"'-dieckol (**115**) from the Korean brown alga *Ecklonia cava* included the "ability to act against drug-resistant HIV-1 strains" by a mechanism that involved inhibition of cytopathic effects, as well as inhibition of HIV-1 reverse transcriptase enzyme \[[@B110-marinedrugs-18-00005]\]. Zhao and colleagues established that truncateol M (**116**) isolated from a culture of the sponge-associated fungus *Truncatella angustata* demonstrated potent activity against influenza A infections by a mechanism that targeted the virion assembly and release step, putatively becoming "a model structure of antiviral lead for further modification" \[[@B111-marinedrugs-18-00005]\]. Chen and colleagues determined that the alkaloid neoechinulin B (**117**) isolated from the marine-derived fungus *Eurotium rubrum* showed potent inhibition of H1N1 influenza A virus by binding to the influenza virion envelope hemagglutin, thus "disrupting its interaction with the sialic acid receptor" on host cells \[[@B112-marinedrugs-18-00005]\].

An additional 15 marine natural products (**118**--**132**), listed in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"} and shown in [Figure 1](#marinedrugs-18-00005-f001){ref-type="fig"}, demonstrated antiviral activity, but the mechanism of action of these compounds remained undetermined at the time of publication. Li and colleagues isolated a novel khayanolide, thaixylomolin I (**118**) from the seeds of the Trang (South Thailand) mangrove plant *Xylocarpus moluccensis*, which inhibited potent activity against influenza virus strain H1N1 \[[@B113-marinedrugs-18-00005]\]. Chen and colleagues contributed a new prenylated dihydroquinolone derivative 22-*O*-(N-Me-L-valyl)-21-epi-aflaquinolone B (**119**), produced by the mycelia of an *Aspergillus* sp. fungus derived from a South China Sea gorgonian *Muricella abnormaliz,* that inhibited respiratory syncytial virus influenza A virus H1N1 "with a high therapeutic ratio" \[[@B114-marinedrugs-18-00005]\]. Nong and colleagues found that two novel lactones territrem D and arisugacin A (**120, 121**) from a fungus *Aspergillus terreus* SCSGAF0162 derived from a South China sea gorgonian *Echinogorgia aurantiaca* exhibited HSV-1 activity "under non-cytotoxic concentrations" \[[@B115-marinedrugs-18-00005]\]. Li and colleagues isolated a novel isoindolinone-type alkaloid chartarutine B (**122**) from the marine sponge-associated fungus *Stachybotrys chartarum*, which displayed moderate inhibitory activity HIV-1, noting that "side chain variation directly affected the inhibitory effects" \[[@B116-marinedrugs-18-00005]\]. Gupta and colleagues purified debromoaplysiatoxin (**123**) from the marine Singaporan cyanobacterium *Trichodesmium erythraeum*, which inhibited Chikungunya virus with "minimal cytotoxicity", and probably targeted the viral replication cycle after "viral entry" \[[@B117-marinedrugs-18-00005]\]. Pardo-Vargas and colleagues reported that the new diterpene dolabelladienol A (**124**) isolated from the Brazilian marine brown alga *Dictyota pfaffii* had potent activity against HIV-1 and, owing to "low cytotoxicity", appeared to be a "promising anti-HIV-1 agent" \[[@B118-marinedrugs-18-00005]\]. Cheng and colleagues noted that one of the dolastane diterpenes isolated from the South China sea brown alga *Dictyota plectens*, namely 13-deacetoxyamijidictyol (**125**), showed inhibitory activity against wild-type HIV-1 replication, thus proposing that "*Dictyota* algae may be a potential source of antiviral lead compounds" \[[@B119-marinedrugs-18-00005]\]. Yamashita and colleagues investigated the effect of two polybrominated diphenyl ethers (**22, 23**) isolated from the Indonesian marine sponge *Dysidea granulosa* on the hepatitis B virus (HBV) core promoter activity, as well as the production of HBV DNA, suggesting that they may become "candidate lead compounds for the development of anti-HBV drugs" \[[@B120-marinedrugs-18-00005]\]. Cao and colleagues discovered that a new steroid echrebsteroid C (**126**) from the South China sea gorgonian *Echinogorgia rebekka* evidenced high activity against respiratory syncytial virus, a common cause of lower respiratory tract disease in infants and children, as well as a high therapeutic index, thus "suggesting it might be useful as a potential antiviral agent" \[[@B121-marinedrugs-18-00005]\]. Jia and colleagues showed that one of two enantiomeric dimers, namely (+)-pestaloxazine A (**127**), isolated from a *Pestalotiopsis* sp. fungus derived from a soft coral, showed potent antiviral activity towards enterovirus 71, a small, single-stranded RNA virus that may cause hand, foot, and mouth disease associated with neurological complications in children and infants \[[@B122-marinedrugs-18-00005]\]. Eom and colleagues evaluated phlorofucofuroeckol-A (**10**), isolated from the edible brown alga *Eisenia bicyclis* against murine norovirus, a leading cause of gastroenteritis, noting that, because of its strong anti-norovirus activity and high therapeutic index, it appeared "phlorotannins could be used as a potential source of natural antiviral agents" \[[@B123-marinedrugs-18-00005]\]. Cheng and colleagues discovered a new *seco*-cembranoid secocrassumol (**128**) from the marine soft coral *Lobophytum crassum*, which showed significant activity against human cytomegalovirus, a common herpesvirus infection in humans \[[@B124-marinedrugs-18-00005]\]. Using ligand-based pharmacophore mapping, Dineshkumar and colleagues demonstrated that the polycyclic macrolide sporolide B (**129**) isolated from the marine actinomycete *Salinispora tropica* showed significant inhibition of the HIV-1 reverse transcriptase, and thus "could be a possible drug candidate for HIV" \[[@B125-marinedrugs-18-00005]\]. Shin and colleagues isolated two new depsipeptides stellettapeptins A and B (**130, 131**) from an extract of the Australian marine sponge *Stelletta* sp. with significant HIV-inhibitory properties, suggesting that "this class of peptides may hold promise as anti-HIV agents" \[[@B126-marinedrugs-18-00005]\]. Sun and colleagues characterized a new tetramic acid derivative trichobotrysin A (**132**) isolated from the culture of South China sea *Trichobotrys effuse* DFFSCS021 that inhibited herpes simplex virus type-1, responsible for lifelong oral infections in humans \[[@B127-marinedrugs-18-00005]\].

2.5. Anthelmintic Activity {#sec2dot5-marinedrugs-18-00005}
--------------------------

As shown in [Table 1](#marinedrugs-18-00005-t001){ref-type="table"}, only one report was published during 2014--2015 on the anthelmintic pharmacology of marine natural products. Farrugia and colleagues isolated a 6-*N*-acyladenine alkaloid, phorioadenine A (**133**), from the southern Australian marine sponge *Phoriospongia* sp., which displayed "...nematocidal activity against *H. contortus*...slightly weaker than commercial anthelmintics levamisole and closantel", perhaps suggesting that this compound may become a promising lead compound for the development of new anthelmintics \[[@B128-marinedrugs-18-00005]\].

3. Marine Compounds with Antidiabetic and Anti-Inflammatory Activity, and Affecting the Immune and Nervous System {#sec3-marinedrugs-18-00005}
=================================================================================================================

[Table 2](#marinedrugs-18-00005-t002){ref-type="table"} presents the 2014--2015 preclinical pharmacology of marine chemicals (**134**--**218**), which demonstrated either antidiabetic or anti-inflammatory activity, as well as affected the immune or nervous system, and whose structures are depicted in [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}.

3.1. Antidiabetic Activity {#sec3dot1-marinedrugs-18-00005}
--------------------------

As shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"} and [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}, four publications reported on the mode of action of marine-derived antidiabetic compounds (**10**, **134**--**136**). Kang and colleagues contributed to the pharmacology of diabetes by noting that the marine carotenoid fucoxanthin (**134**), isolated from the marine brown alga *Ishige okamurae*, protected cells and organs from oxidative damage induced by high glucose both in vitro and in vivo, concluding that "fucoxanthin may prove to be an effective mediator to control oxidative stress in hyperglycemia" \[[@B155-marinedrugs-18-00005]\]. Maeda and colleagues observed that fucoxanthin and its metabolite, fucoxanthinol (**135**), improved obesity-induced inflammation in adipocyte cells with concomitant suppression of tumor necrosis factor-α and monocyte chemotactic protein-1 RNA expression, thus concluding that fucoxanthin "ameliorates glucose tolerance in the diabetic mice model" \[[@B154-marinedrugs-18-00005]\]. Lee and colleagues reported that octaphlorethol A (**136**) isolated from the marine brown alga *Ishige foliacea* showed a potent anti-hyperglycemic effect in mice by potently binding to α-glucosidase, an enzyme that plays a role in blood glucose control, thus demonstrating its potential use "for treatment of type 2 diabetes mellitus" \[[@B156-marinedrugs-18-00005]\]. You and colleagues showed that the phlorotannin phlorofucofuroeckol-A (**10**) isolated from the brown alga *Ecklonia cava* alleviated postprandial hyperglycemia in diabetic mice by a mechanism that involved significant inhibition of α-glucosidase and α-amylase, thus proposing this natural product "as a nutraceutical for diabetic individuals" \[[@B157-marinedrugs-18-00005]\].

An additional six marine natural products (**137**--**142**), listed in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"} and shown [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}, demonstrated antidiabetic activity, but the mechanism of action of these compounds remained undetermined at the time of publication. Safavi-Hemami and colleagues described a specialized insulin Con-Ins G1 (**137**) used for chemical warfare by the fish-hunting cone snail *Conus geographus*, which appear to have "evolved to act rapidly and potently to cause severe hypoglycemia" \[[@B158-marinedrugs-18-00005]\]. Yamazaki and colleagues found that the sesquiterpene dehydroeuryspongin A (**138**) isolated from the Japanese marine sponge *Euryspongia* sp. inhibited the protein tyrosine phosphatase 1B, considered a key enzyme involved in type II diabetes and obesity because it plays a role in the dephosphorylation of insulin and leptin receptors \[[@B159-marinedrugs-18-00005]\]. Xia and colleagues contributed a new isopimarane diterpene (**139**) isolated from the culture of the fungus *Epicoccum* sp. associated with the marine sea cucumber *Apostichopus japonicus* that potently inhibited α-glucosidase \[[@B160-marinedrugs-18-00005]\]. Shin and colleagues isolated a new benzothioate glycoside suncheonoside A (**140**) from a Korean marine-derived *Streptomyces* strain that promoted adiponectin production during adipogenesis in vitro, thus "suggesting antidiabetic potential" \[[@B161-marinedrugs-18-00005]\]. You and colleagues reported that the lumazine-containing peptide terrelumamide A (**141**), isolated from the culture broth of the Korean marine-derived fungus *Aspergillus terreus*, improved insulin sensitivity and adiponectin production in an in vitro human adipogenesis model \[[@B162-marinedrugs-18-00005]\]. He and colleagues characterized a polyunsaturated lipid (**142**) from the Chinese marine sponge *Xestospongia testudinaria*, which was shown to inhibit protein tyrosine phosphatase 1B, considered as a significant target for the "treatment of type II diabetes and obesity" \[[@B163-marinedrugs-18-00005]\].

3.2. Anti-Inflammatory Activity {#sec3dot2-marinedrugs-18-00005}
-------------------------------

As shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"} and [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}, there was a remarkable increase in anti-inflammatory pharmacology of marine compounds (**143**--**191**) during 2014--2015. The molecular mechanism of action of marine natural products (**143**--**163**) was assessed in both in vitro and in vivo preclinical pharmacological studies in twenty-two papers that used several in vitro models: the murine RAW 264.7 macrophages, a human keratinocyte cell line, a human hepatocarcinoma HepG2 cell line, primary rat brain microglia, and a murine microglia BV-2 cell line.

Taira and colleagues evaluated the anti-inflammatory properties of alcyonolide and its congener (**143, 144**), isolated from the Okinawan soft coral *Cespitularia* sp. in lipopolysaccharide (LPS)-stimulated RAW264.7, observing inhibition of NO as well as gene expression of the proinflammatory genes inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 mRNA \[[@B164-marinedrugs-18-00005]\]. Guo and colleagues extended the pharmacology of the terpenoid astaxanthin (**145**) by reporting that a reduction of oxidative stress in an in vivo model of rat burn injury was concomitant with a decrease in the level of malondialdehyde, an indicator of lipid peroxidation, as well as an increase of antioxidant enzymes superoxide dismutase and catalase, a "protective effect" that held "potential as a new drug treatment of severely burned patients..." \[[@B165-marinedrugs-18-00005]\]. Yang and colleagues reported that the polyketide 8,8′-bieckol (**146**), isolated from the edible marine brown alga *Ecklonia cava*, significantly inhibited both pro-inflammatory NO, prostaglandin E~2~ (PGE~2~), and interleukin 6 (IL-6) production, as well as gene expression by downregulating NF-κB signaling pathway and ROS accumulation in both LPS-stimulated primary macrophages and RAW 264.7 macrophages, thus demonstrating the compound's "anti-inflammatory potential...in systemic inflammatory conditions such as sepsis" \[[@B166-marinedrugs-18-00005]\]. Fernandes and colleagues studied convolutamydine A (**147**), isolated from marine bryozoan *Amathia convoluta*, and two synthesized analogs, and determined that they exhibited significant in vivo and in vitro anti-inflammatory activity by a mechanism that involved reduced leukocyte migration as well as inhibition of the production of the cytokine IL-6, PGE~2~, and NO \[[@B167-marinedrugs-18-00005]\]. Phan and colleagues isolated a new bicyclogermacrene capgermacrene A (**148**) from the Bornean soft coral *Capnella* sp. and observed significant in vitro inhibition of NO production by RAW 264.7 macrophages by inhibition of iNOS expression, proposing this compound as a "promising iNOS inhibiting agent" \[[@B168-marinedrugs-18-00005]\]. Jiménez-Romero and colleagues investigated the effect of the diterpene dactyloditerpenol acetate (**149**) extracted from the Puerto Rican tropical sea hare *Aplysia dactylomela* on *E. coli* LPS-activated rat neonatal microglia in vitro, observing the potent inhibition of both thromboxane B~2~ and superoxide anion (O~2~^−^) generation, proinflammatory mediators associated with neuroinflammation, concluding that the data "support further development" of this compound \[[@B169-marinedrugs-18-00005]\]. Two studies extended the anti-inflammatory pharmacology of dieckol (**150**) isolated from the brown alga *Ecklonia cava*: Choi and colleagues demonstrated the compound inhibited LPS-induced iNOS expression by affecting mitogen-activated protein kinases (MAPK), "significantly p38MAPK" in the mouse macrophage 264.7 cell line in vitro \[[@B170-marinedrugs-18-00005]\], while Kang and colleagues demonstrated that dieckol suppressed production of macrophage-derived chemokine, C--C motif chemokine 22, an inflammatory chemokine that controls leukocyte movements by down-regulating the activation of the signal transducer and activator of transcription (STAT)1 signaling pathway in human keratinocytes \[[@B171-marinedrugs-18-00005]\]. Lin and colleagues characterized the anti-inflammatory effects of the diterpene excavatolide B (**151**) isolated from the cultured Formosan marine gorgonian *Briareum excavatum* and observed that, in vitro, it inhibited iNOS and COX-2 mRNA expression in LPS-treated murine RAW 264.7 macrophages, while in vivo it attenuated carrageenan-induced rat paw inflammation and pain, thus concluding that "excavatolide B may serve as a useful therapeutic agent for the treatment of acute inflammation" \[[@B172-marinedrugs-18-00005]\]. Chen and colleagues investigated the antinociceptive properties of flexibilide (**152**), isolated from the Australian soft coral *Sinularia flexibilis* in the rat chronic injury model of neuropathic pain, observing significant analgesic effects concomitant with suppression of iNOS expression in microglia and astrocytes in the spinal dorsal horn, accompanied with upregulation of transforming growth factor-β1 (TGF-β1), "suggesting involvement of TGF-β1 in the anti-neuroinflammatory and analgesic effects" \[[@B173-marinedrugs-18-00005]\]. Kim and colleagues reported that a polyhydroxyflavone (**153**) isolated from the marine alga *Hizikia fusiforme* suppressed LPS-stimulated RAW 264.7 cells' release of pro-inflammatory cytokines, as well as both iNOS and COX-2 expression, by attenuating nuclear transcription factor-κB (NF-κB) translocation, and thus might become a "potential therapeutic agent for patients with, or at risk of, septic shock or other inflammatory diseases" \[[@B174-marinedrugs-18-00005]\]. Wijesinghe and colleagues evaluated 5β-hydroxypalisadin B (**154**), a brominated secondary metabolite isolated from the Malaysian marine red alga *Laurencia snackeyi*, on LPS-stimulated RAW 264.7 macrophages and observed significant reduction of several pro-inflammatory cytokines, NO, and PGE~2~ generation, and thus concluded that the compound might help development of "an active ingredient in pharmaceutical, nutraceutical..." applications \[[@B175-marinedrugs-18-00005]\]. Huang and colleagues characterized two novel biscembranes glaucumolides A and B (**155, 156**) from the cultured soft coral *Sarcophyton glaucum* that significantly inhibited O~2~^-^ generation and elastase release in human neutrophils, while also reducing expression of iNOS and COX-2 in LPS-treated murine RAW 264.7 macrophages, concluding that these two compounds "might be useful for future biomedical applications" \[[@B176-marinedrugs-18-00005]\]. Yu and colleagues determined that the effects of phlorofucofuroeckol-B (**157**), isolated from the marine alga *Ecklonia stolonifera*, on the decreased production of pro-inflammatory mediators by LPS-stimulated BV-2 microglia cells, as well as reduced COX-2 and iNOS expression, resulted from inhibition of the iκB-α/NF-κB and Akt/ERK/JNK pathways, thus proposing that this compound might be "considered as a therapeutic agent against neuroinflammation" \[[@B177-marinedrugs-18-00005]\]. Babskota and colleagues isolated a new phosphatidylglycerol (**158**) from an extract of the marine red alga *Palmaria palmata*, also commonly known as dulse, which strongly inhibited NO release from LPS treated murine RAW 264.7 macrophages, probably by a mechanism that down-regulated iNOS, thus suggesting that "consumption of dulse as a functional food may help to reduce inflammation associated with various diseases" \[[@B178-marinedrugs-18-00005]\]. Itoh and coleagues showed that reduced scytonemin (**159**) isolated from the cosmopolitan colonial cyanobacterium *Nostoc commune* strongly inhibited LPS and interferon-γ-induced NO production in murine macrophage RAW 264.7 macrophages, by generating reactive oxygen species by activation of the phosphatidylinositol-3-kinase/Akt and the p38 mitogen-activated protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathways \[[@B179-marinedrugs-18-00005]\]. Lillsunde and colleagues reported that a norcembranoid sinuleptolide (**160**) isolated from the Indian soft coral *Sinularia kavarattiensis* potently modulated both morphology and release of pro-inflammatory and anti-inflammatory mediators by LPS-treated rat primary microglial cells in vitro, thus decreasing microglia activation, which has been hypothesized to be involved in the "progression of chronic neurodegenerative diseases.. and central nervous system (CNS) homeostasis" \[[@B180-marinedrugs-18-00005]\]. Thao and colleagues contributed a new polyhydroxylated steroid sarcopanol A (**161**) from the Vietnamese soft coral *Sarcophyton pauciplicatum* that inhibited tumor necrosis factor (TNF)-α and interferon (IFN)γ-induced expression of COX-2, iNOS, and intercellular adhesion molecule-1 (ICAM-1) in the spontaneously transformed immortal human keratinocyte cell line HaCaT via inhibition of NF-κB signaling pathway activation \[[@B181-marinedrugs-18-00005]\]. Thao and colleagues investigated the diterpenoid sinumaximol (**162**), isolated from the marine soft coral *Sinularia maxima*, and determined that it significantly inhibited TNF-α-induced NF-κB transcriptional activity in a human hepatocarcinoma HepG2 cell line, while concomitantly inhibiting the expression of pro-inflammatory iNOS and ICAM-1mRNA expression, thus supporting the "therapeutic potential as anti-inflammatory" of this compound \[[@B182-marinedrugs-18-00005]\]. Quang con colleagues determined that tanzawaic acid A (**163**), isolated from a marine fungus *Penicillium* sp. SF-6013 derived from the Pacific sea urchin *Brisaster latifrons*, inhibited both NO and PGE~2~ production from LPS-activated murine BV-2 microglia cells and RAW 264.7 murine macrophages, while suppressing iNOS and COX-2 expression and inhibiting protein tyrosine phosphatase 1B \[[@B183-marinedrugs-18-00005]\].

In contrast to the marine compounds (**143**--**163**) with described anti-inflammatory mechanisms of action described in the preceding paragraph, and as shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"}, for marine compounds (**164**--**191**), only anti-inflammatory activity (IC~50~) was reported, but the molecular mechanism of action of these marine-derived compounds remained undetermined at the time of publication: a new highly oxygenated meroterpene aspertetranone D (**164**) isolated from the marine algal-associated fungus *Aspergillus* sp. ZL0-1b14 \[[@B184-marinedrugs-18-00005]\]; a novel 6,12-dichlorobriarene diterpenoid briarenolide J (**165**), two briarane diterpenoids briarenolides K and L (**166, 167**), and the briarenolides U--W (**168**--**169**), all compounds isolated from the Taiwanese octocoral *Briareum* sp. \[[@B185-marinedrugs-18-00005],[@B186-marinedrugs-18-00005],[@B187-marinedrugs-18-00005]\]; two new briarane diterpenoids briaviolides E and I (**170, 171**), isolated from the Taiwanese soft coral *Briareum violacea* \[[@B188-marinedrugs-18-00005]\]; a new pigmented phenazine compound dermacozine H (**172**), isolated from the actinomycete *Dermacoccus abyssi* sp. nov. strain MT1.1, isolated from a Mariana Trench sediment at a depth of 10,898 m \[[@B189-marinedrugs-18-00005]\]; a novel sesquiterpene dysifragilone A (**173**), isolated from the South China Sea sponge *Dysidea fragilis* \[[@B190-marinedrugs-18-00005]\]; a new xenicane 4α-hydroxypachylactone (**174**), isolated from a Chinese brown alga *Dictyota plectens* \[[@B191-marinedrugs-18-00005]\]; a polyketide comaparvin (**175**), isolated from the Taiwanese marine crinoid *Comanthus bennetti* \[[@B192-marinedrugs-18-00005]\]; two novel eunicellin-type diterpenoids hirsutalins N and S (**176, 177**) and a new tocopherol-derived metabolite hirsutocospiro A (**178**), isolated from the Taiwanese soft coral *Cladiella hirsuta* \[[@B193-marinedrugs-18-00005],[@B194-marinedrugs-18-00005],[@B195-marinedrugs-18-00005]\]; a new cembranoid isosinulaflexiolide K (**179**), isolated from cultured Taiwanese soft corals *Sinularia sandensis* and *Sinularia flexibilis* \[[@B196-marinedrugs-18-00005]\]; a novel 9,11-secogorgosteroid klyflaccisteroid F (**180**), isolated from the Taiwaneses soft coral *Klyxum flaccidum* \[[@B197-marinedrugs-18-00005]\]; new eunicellin-type diterpenoids krempfielins N (**181**), Q (**182**), and R (**183**), isolated from a Taiwanese soft coral *Cladiella krempfi* \[[@B198-marinedrugs-18-00005],[@B199-marinedrugs-18-00005]\]; a methylfarnesylquinone (**184**), isolated from the Taiwanese marine brown alga *Homeostrichus formosana* \[[@B200-marinedrugs-18-00005]\]; a novel steroid monanchosterol B (**185**), isolated from the Korean sponge *Monanchora* sp. \[[@B201-marinedrugs-18-00005]\]; a oxygenated steroid derivative (**186**), isolated from the Vietnamese starfish *Protoreaster nodosus* \[[@B202-marinedrugs-18-00005]\]; a new spirobisnaphthalene rhytidenone C (**187**), isolated from an extract of a cultured fungal endophyte *Rhytidhysteron* sp. AS21B isolated from a Thailandese mangrove area \[[@B203-marinedrugs-18-00005]\]; a known terpenoid sarcocrassocolide E (**188**), isolated from a Taiwanese soft coral *Sarcophyton crassocaule* \[[@B204-marinedrugs-18-00005]\]; a new cembrane diterpenoid sinulacembranolide A (**189**), isolated from the Taiwanese soft coral *Sinularia gaweli* \[[@B205-marinedrugs-18-00005]\]; a new eudesmane-type sesquiterpene thomimarine B (**190**), isolated from the fungus *Penicillium thomii* KMM 4667 isolated from the Japanese sea grass *Zostera marina* \[[@B206-marinedrugs-18-00005]\]; and a novel diterpenoid tortuosene A (**191**), isolated from the Taiwanese soft coral *Sarcophyton tortuosum* \[[@B207-marinedrugs-18-00005]\].

3.3. Marine Compounds with Activity on the Immune System {#sec3dot3-marinedrugs-18-00005}
--------------------------------------------------------

As shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"} and [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}, the preclinical pharmacology of marine compounds that affected the *immune* system showed a decline, as previously reported in this series.

Kwan and colleagues reported that the peptide grassypeptolide A (**192**), isolated from the marine cyanobacterium *Lyngbya confervoides,* inhibited IL-2 production and proliferation of activated T cells by inhibiting the protease dipeptidyl peptidase 8, probably by binding at inner cavity of the enzyme at two distinct sites \[[@B208-marinedrugs-18-00005]\]. Wang and colleagues isolated a pair of novel bisheterocyclic quinolone-imidazole alkaloids (+)- and (^\_^) spiroreticulatine (**193**) from the South China sea sponge *Fascaplysinopsis reticulata*, which showed inhibition of IL-2 production by Jurkat T cells \[[@B209-marinedrugs-18-00005]\]. Kicha and colleagues determined that the cyclic steroid glycoside luzonicoside A (**194**), isolated from the starfish *Echinaster luzonicus*, potently enhanced lysosomal activity, ROS level elevation, and NO synthesis in RAW 264.7 murine macrophages, thus seeming "promising for further investigation as a potent immunomodulatory agent" \[[@B210-marinedrugs-18-00005]\]. Pislyagin and colleagues investigated a triterpene glycoside typicoside C~1~ (**195**), isolated from the sea cucumber *Actinocucumis typica*, and observed that it demonstrated strong immunostimulatory effect on ROS formation in mouse peritoneal macrophages in vitro, with concomitant low cytotoxicity \[[@B211-marinedrugs-18-00005]\].

3.4. Marine Compounds Affecting the Nervous System {#sec3dot4-marinedrugs-18-00005}
--------------------------------------------------

As shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"} and [Figure 2](#marinedrugs-18-00005-f002){ref-type="fig"}, in 2014--2015, the preclinical marine *nervous* system pharmacology of compounds (**196**--**211**) described several mechanism of action: at the nicotinic acetylcholine receptor and potassium channels, with conopeptides, and in models of antinociception and neuroprotection.

Four marine compounds were shown to bind nicotinic acetylcholine receptors (nACHR) (**199**, **207**, **210**) and potassium (K^+^) channels (**208**). Kasheverov and colleagues determined the effect of 6-bromohypaphorine (6-BHP) (**199**), isolated from the marine nudibranch mollusk *Hermissenda crassicornis*, on different nAChR, demonstrating that, because 6-BHP competed with α-bungarotoxin for binding to the human α7 nAChR, it was the "first low-molecular weight compound from (a) marine source which (was) an agonist of the nACHR subtype" \[[@B215-marinedrugs-18-00005]\]. Bourne and colleagues conducted detailed studies to determine the molecular pharmacology of the macrocylic imine phycotoxin pinnatoxin A (**207**), originally isolated from the digestive glands of the mollusk *Pinna attenuata*, towards neuronal α7nACHR, observing that the bicyclic EF-ketal ring was a novel binding determinant for mediating polar versus non-polar interactions, and thus is able to "confer nAChR subtype selectivity... (of) these prevalent marine biotoxins" \[[@B223-marinedrugs-18-00005]\]. Rodríguez and colleagues discovered a novel peptide PhcrTx1 (**208**) from the sea anemone *Phymanthus crucifer* that inhibited voltage-gated K^+^ ion channels, including acid-sensing ion channel (ASIC) (IC~50~ = 100 nM), and that would represent "the first member of a new structural group of sea anemone toxins acting on ASIC" \[[@B224-marinedrugs-18-00005]\]. Aráoz and colleagues extended the pharmacology of the "fast-acting" lipophilic marine toxin 13,19-desmethyl spirolide C (**210**), extracted from cultures of the dinoflagellate *Alexandrium ostenfeldii*, defining the mode of action and molecular targets using in vitro electrophysiological experiments, and thus showing that the toxin blocked human neuronal nACHR (IC~50~ = 0.2 nM) with high affinity, observations supported by molecular docking experiments "highlighting the nicotinic basis of the neurotoxicity of (this toxin) to mammal(ian)....peripheral and central nervous system" \[[@B227-marinedrugs-18-00005]\].

Three studies extended the pharmacology of conopeptides (**201**--**203**). Wang and colleagues discovered a novel α-conotoxin Mr1.7 (**201**) in the venom of the marine snail *Conus marmoreus* that inhibited α3β2, α9α10, and α6/α3β2β3 nACHR subtypes (IC~50~ = 53.1, 185.7, and 284.2 nM, respectively), noting that the PE residues at the N-terminal sequence of Mr1.7 were "important for modulating activity and selectivity" \[[@B217-marinedrugs-18-00005]\]. Zhou and colleagues reported the expression and sodium channel activity of peptide It16a (**202**), a novel framework XVI conotoxin from the M-superfamily isolated from the worm-hunting snail *C. litteratus,* and, using a variety of electrophysiological techniques, demonstrated that it preferentially inhibited voltage-gated Na^+^ channels (apparent IC~50~ = 1 µM) in mammalian sensory neurons, with the authors noting "It16a ...has similar function as µ-conotoxins" \[[@B218-marinedrugs-18-00005]\]. Li and colleagues extended the pharmacology of Vt3.1 conotoxin (**203**), isolated from the venom of the marine cone snail *C. vitulinus*, and demonstrated that it preferentially inhibited large conductance, voltage, and Ca^2+^ activated K^+^ (BK) channels containing the *β*4 subunit (IC~5~ = 8.5 µM), which appears to be present in brain and neuronal functions by a mechanism that required electrostatic interactions with the channel protein, making it an excellent tool "uniquely suited in neuroscience involving BK channels" \[[@B219-marinedrugs-18-00005]\].

Two studies reported marine compounds (**198**, **200**) that contributed to nociceptive pharmacology. Cavalcante-Silva and colleagues assessed the mechanism involved in in vivo antinociception produced by the bisindole alkaloid caulerpine (**198**), isolated from the marine alga *Caulerpa*, demonstrating that, in the in vivo murine writhing test, the effect was likely mediated by "pathways involving α2-adrenoceptors and 5-HT3 receptors", thus proposing cualerpine as a possible "dual-action analgesic drug(s)" \[[@B214-marinedrugs-18-00005]\]. Chen and colleagues investigated the anti-neuropathic properties of the antimicrobial peptide piscidin (**200**) and observed that the compound demonstrated in vivo anti-nociceptive effects in a rat model of neuropathy by a signaling mechanism that suppressed up-regulation of interleukin-1 in microglia and phosphorylated mammalian target of rapamycin in astrocytes, concluding it "may have potential for development as an alternative pain-alleviating agent" \[[@B216-marinedrugs-18-00005]\].

The neuroprotective activity of marine compounds (**196**, **197**, **205**, **206**, **211**) was reported in five studies. Wu and colleagues observed that the novel (Z)-7,4′-dimethoxy-6-hydroxy-aurone-4-O-*β*-glucopyranoside (**196**) isolated from the endophytic fungus *Penicillium citrinum* of the mangrove *Bruguiera gymnorrhyza* derivative decreased 1-methyl-4-phenylpyridium-induced neurotoxicity in rat pheochromocytoma PC12 cells in vitro by a mechanism that elevated mitochondrial membrane potential, decreased DNA fragmentation, and inhibited apoptosis \[[@B212-marinedrugs-18-00005]\]. Hjornevik and colleagues completed an extensive in vitro "neurotoxicological" study with the marine algal toxin azaspiracid-1 (**197**) and observed rat PC12 cells' differentiation-related morphological changes associated with the expression of the PC12-associated neuronal differentiation marker peripherin on neurite-like processes, suggesting this molecule "triggers a differentiation process" \[[@B213-marinedrugs-18-00005]\]. Yamagishi and colleagues explored the structure--activity relationship of LLG-3 (**205**), a ganglioside isolated from the starfish *Linchia laevigata*, and discovered that the methyl group at C8 of the terminal sialic acid residue was of critical significance for neuritogenic activity. Furthermore, detailed signaling studies revealed the "activation of mitogen-activated protein kinase signaling pathway" \[[@B221-marinedrugs-18-00005]\]. Cassiano and colleagues, using chemical proteomics, noted that the terpenoid heteronemin (**206**), isolated from the marine sponge *Hyrtios* sp., targeted TDP-43, a major component of inclusions that characterize amyotrophic lateral sclerosis and front-temporal lobar degeneration, by lowering its affinity "towards nucleic acids", and thus becoming a "relevant chemical tool in the study of TDP-43 related processes" \[[@B222-marinedrugs-18-00005]\]. Shimizu and colleagues provided the "first report" that the pro-electrophilic sesquiterpene zonarol (**211**), isolated from the Japanese brown alga *Dictyopteris undulata*, provided neuroprotection by activating the nuclear factor (erythroid-derived-2)-like 2/antioxidant responsive element Nrf2/ARE pathway, inducing phase-2 enzymes and providing oxidative stress protection to cerebrocortical neurons in vitro, concluding that the compound "represents a lead compound for the treatment of chronic neurodegenerative diseases associated with oxidative stress" \[[@B228-marinedrugs-18-00005]\].

As shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"}, three marine compounds were shown to modulate other molecular targets, that is, γ-aminobutyric acid (GABA) receptor (**209**), and the acetylcholinesterase (**204**) and butyrylcholinesterase enzyme (**10**). Lee and colleagues discovered that the pigment echinochrome A (**204**), isolated from the sea urchin *Scaphechinus,* inhibited acetylcholinesterase (IC~50~ = 16.4 µM) by an irreversible and uncompetitive mechanism that might be useful in "treating acetylcholine-limited diseases", such as Alzheimer's disease and "other forms of dementia" \[[@B220-marinedrugs-18-00005]\]. Eltahawy and colleagues isolated of a new ceramide (**209**) from the Red sea soft coral *Sarcophyton auritum,* which demonstrated antiepileptic activity in vivo with a central nervous system depressing mechanism that appeared to involve "GABA receptor modulation rather than serotonin receptor inhibition" \[[@B226-marinedrugs-18-00005]\]. Choi and colleagues reported that the polyphenol phlorofucofuroeckol-A (**10**), isolated from the Korean brown alga *Ecklonia cava*, potently inhibited butyrylcholinesterase, a novel target for Alzheimer's disease, suggesting that "phlorotannins ... to be very promising medicinal compounds" \[[@B225-marinedrugs-18-00005]\].

In contrast to the marine compounds affecting the nervous system with investigated mechanisms of action discussed above, and as shown in [Table 2](#marinedrugs-18-00005-t002){ref-type="table"}, for marine compounds (**120**, **121**, **212**-**218**), only an IC~50~ was reported, but the molecular mechanism of action of these compounds remained undetermined at the time of publication: an Australian marine-sponge *Aplysinella* sp.-derived aplysinellamide-1 (**212**) \[[@B229-marinedrugs-18-00005]\], the novel lactones territrem D, and arisugacin A (**120, 121**) from a fungus *Aspergillus terreus* SCSGAF0162 derived from a South China sea gorgonian *Echinogorgia aurantiaca* \[[@B115-marinedrugs-18-00005]\]; an Indian marine cone snail *Conus araneosus* ar3j peptide (**213**) \[[@B230-marinedrugs-18-00005]\]; a new steroid (**214**) from a fungus *Dichotomomyces cejpii* isolated from an Australian marine sponge *Callyspongia* cf. C. *flammea* \[[@B231-marinedrugs-18-00005]\]; a novel genuanine (**215**) isolated from Cape Verde marine cone snail *Conus genuanus* \[[@B232-marinedrugs-18-00005]\]; a bromotyrosine alkaloid homoaerothionin (**216**) isolated from the Thai sponge *Acanthodendrilla* sp. \[[@B233-marinedrugs-18-00005]\]; a new alkyl amide mooreamide A (**217**) from the Papua New Guinean marine cyanobacterium *Moorea bouillonii* \[[@B234-marinedrugs-18-00005]\]; and a hydroxyoctaprenyl 1′,4′-hydroquinone (**218**) isolated from the Italian marine sponge *Sarcotragus spinosulus* \[[@B235-marinedrugs-18-00005]\].

4. Marine Compounds with Miscellaneous Mechanisms of Action {#sec4-marinedrugs-18-00005}
===========================================================

The 2014--2015 preclinical pharmacology of 83 marine compounds (**219**--**300**) with miscellaneous mechanisms of action is shown in [Table 3](#marinedrugs-18-00005-t003){ref-type="table"}, with their corresponding structures presented in [Figure 3](#marinedrugs-18-00005-f003){ref-type="fig"}. Because, at the time of publication, a comprehensive pharmacological characterization of these compounds remained unavailable, their assignment to a particular drug class will probably require further investigation.

As reported in the peer-reviewed literature, [Table 3](#marinedrugs-18-00005-t003){ref-type="table"} presents the pharmacological activity, an IC~50~, and a molecular mechanism of action of the following marine natural compounds: sea anemone *Aiptasia diaphana* toxic peptide AdE-1 (**219**) \[[@B236-marinedrugs-18-00005]\]; sponge alkaloid aaptamine (**220**) \[[@B237-marinedrugs-18-00005]\]; dinoflagellate *Amphidinium* sp. polyketide amphirionin-4 (**221**) \[[@B238-marinedrugs-18-00005]\]; algal terpenoid astaxanthin (**145**) \[[@B239-marinedrugs-18-00005]\]; sponge alkaloids bastadins 6 and 16 (**222, 223**) \[[@B240-marinedrugs-18-00005]\]; brown alga *Eisenia bicyclis* polyketide 6,6-bieckol (**224**) \[[@B241-marinedrugs-18-00005]\]; *Streptomyces* sp. strain CNH-287 alkaloid (-)-chlorizidine A (**225**) \[[@B242-marinedrugs-18-00005]\]; soft coral *Cladiella australis* dihydroaustrasulfone alcohol (**226**) \[[@B243-marinedrugs-18-00005],[@B244-marinedrugs-18-00005]\]; edible brown alga *Ishige okamurae* terpenoid diphlorethohydroxycarmalol (**227**) \[[@B245-marinedrugs-18-00005]\]; sea urchin *Scaphechinus mirabilis* alkaloid echinochrome A (**204**) \[[@B246-marinedrugs-18-00005],[@B247-marinedrugs-18-00005]\]; brown alga *Ecklonia stolonifera* polyketide eckol (**228**) \[[@B248-marinedrugs-18-00005]\]; sponge derived fungus *Dichotomomyces cejpii* terpenoid emindole SB (**229**) \[[@B249-marinedrugs-18-00005]\]; Arctic *Streptomyces nitrosporeus* YBH10-5 farnesylquinone (**230**) \[[@B250-marinedrugs-18-00005]\]; fungus *Stachybotrys longispora* FG216 pyrano indolone alkaloid fibrinolytic compound 1 (**231**) \[[@B251-marinedrugs-18-00005]\]; fungus *Paecilomyces formosus* formosusin A (**232**) \[[@B252-marinedrugs-18-00005]\]; brown alga *Ecklonia cava* phlorotannin fucodiphlorethol G (**233**) \[[@B253-marinedrugs-18-00005]\]; green alga *Spirogyra* sp. polyphenol gallic acid (**234**) \[[@B254-marinedrugs-18-00005]\]; cyanobacterium *Schizothrix* sp. gallinamide A (**235**) \[[@B255-marinedrugs-18-00005]\]; sponge *Stylissa aff. carteri* girolline (**236**) \[[@B256-marinedrugs-18-00005]\]; sponge *Spongionella* sp. terpenoids gracilins H, A, and L (**237--239**) \[[@B257-marinedrugs-18-00005]\]; new anemone *Heteractis crispa* Kunitz-type polypeptides HCRG1 and HCRG2 (**240, 241**) \[[@B258-marinedrugs-18-00005]\]; new sponge *Hyrtios* sp. sesterterpenoid 2 (**242**) \[[@B259-marinedrugs-18-00005]\]; sponge *Ircinia ramose* irciniastatin A (**243**) \[[@B260-marinedrugs-18-00005]\]; ascidian *Eudistoma* cf. *rigida* polyketide lejimalide C (**244**) \[[@B261-marinedrugs-18-00005]\]; red alga *Laurencia brongniartii* brominated indole (**245**) \[[@B262-marinedrugs-18-00005]\]; sponge *Neopetrosia* sp. pyridine nucleoside neopetroside A (**246**) \[[@B263-marinedrugs-18-00005]\]; edible brown alga *Ecklonia stolonifera* phlorotannin phlorofucofuroeckol-A (**10**) \[[@B264-marinedrugs-18-00005]\]; sponge *Theonella swinhoei* peptide polytheonamide B (**247**) \[[@B265-marinedrugs-18-00005]\]; green alga *Codium fragile* terpenoid siphonaxanthin (**248**) \[[@B266-marinedrugs-18-00005]\]; deep-sea derived fungus *Spiromastix* sp. MCCC 3A00308 spiromastixones J and L (**57, 249**) \[[@B267-marinedrugs-18-00005]\]; bacteria *Thalassospira* sp. CNJ328 and *Tistrella bauzanensis* TIO7329 thalassospiramide C (**250**) \[[@B268-marinedrugs-18-00005]\]; mangrove fungus *Xylaria* sp. xyloketal B (**251**) \[[@B269-marinedrugs-18-00005],[@B270-marinedrugs-18-00005]\]; and sponge *Xestospongia testudinaria* brominated polyunsaturated lipid (**252**) \[[@B271-marinedrugs-18-00005]\].

Also consolidated in [Table 3](#marinedrugs-18-00005-t003){ref-type="table"} is the pharmacological activity (IC~50~ for enzyme or receptor inhibition) of marine-derived compounds (**253**--**300**), but the mechanism of action remained undetermined at the time of publication: a dinoflagellate *Dinophysis acuminate* new polyether macrolide acuminolide A (**253**) \[[@B272-marinedrugs-18-00005]\]; fungus *Alternaria alternata* alternariol derivatives (**255**--**257**) \[[@B136-marinedrugs-18-00005]\]; bacterium *Streptomyces* sp. linear peptide ahpatinin Ac (**254**) \[[@B273-marinedrugs-18-00005]\]; ascidian *Aplidium* sp. new dipeptide apliamide D (**258**) \[[@B274-marinedrugs-18-00005]\]; fungi *Penicillium thomii* and *P. lividum* new meroterpenoids austalides 4 and 9 (**259, 260**) \[[@B275-marinedrugs-18-00005]\]; *Streptomyces axinellae* axinelline A (**261**) \[[@B276-marinedrugs-18-00005]\]; dinoflagellate *Karenia brevisulcata* polyether brevisulcatic acid-4 (**262**) \[[@B277-marinedrugs-18-00005]\]; green alga *Caulerpa racemose* 4′,5′--dehydrodiodictyonema A (**263**) \[[@B278-marinedrugs-18-00005]\]; sponge *Dactylospongia metachromia* sesquiterpenes nakijiquinone N (**264**), nakijinol C (**266**), and known analog 18-hydroxy-5-*epi*-hyrtiophenol (**265**) \[[@B279-marinedrugs-18-00005]\]; ascidian *Didemnum* sp. spiroketals didemnaketals D and E (**267, 268**) \[[@B280-marinedrugs-18-00005]\]; sponge *Dysidea avara* sesquiterpene dysiquinol D (**269**) \[[@B281-marinedrugs-18-00005]\]; brown alga *Laminaria japo*nica terpenoid fucoxanthin (**134**) \[[@B282-marinedrugs-18-00005]\]; sponge *Xestospongia testudinaria* halenaquinol sulfate (**270**) \[[@B283-marinedrugs-18-00005]\]; sponge *Xetospongia* sp. halenaquinone derivative, 1-hydroxyethylhalenaquinone (**271**) \[[@B284-marinedrugs-18-00005]\]; sponge *Stylissa massa* and *S. flabelliformis* bromopyrrole alkaloids (**272**--**274**) \[[@B285-marinedrugs-18-00005]\]; sponge *Callyspongia* sp. hymenialdisine (**275**) \[[@B286-marinedrugs-18-00005]\]; sponge *Hyattella* sp. hyattellactone A (**276**) \[[@B287-marinedrugs-18-00005]\]; sponge *Hippospongia lachne* sesterterpene hippolide derivative (**277**) \[[@B288-marinedrugs-18-00005]\]; sponge *Suberea ianthelliformis* ianthelliformisamines A, B, and C (**278, 7, 8**) \[[@B289-marinedrugs-18-00005]\]; sponge *Plakortis* cfr. *lita* sterols incisterols A5 and A6 (**279, 280**) \[[@B290-marinedrugs-18-00005]\]; soft coral *Lobophytum crissum* cembranoid diterpene 2,16:7*S*,8*S*,-diepoxy 1,3,11,15-cembratetraene (**281**) \[[@B291-marinedrugs-18-00005]\]; red alga *Laurencia okamurai* laurene-type sesquiterpenoid laurokamurane A (**282**) \[[@B292-marinedrugs-18-00005]\]; gorgonian *Echinogorgia pseudossapo* alkaloid malonganenone L (**283**) \[[@B293-marinedrugs-18-00005]\]; fungus *Hansfordia sinuosae* sesquiterpenoid punctaporonin K (**284**) \[[@B294-marinedrugs-18-00005]\]; fungus *Aspergillus versicolor* ZLN-60 cyclic peptide psychrophilin G (**285**) \[[@B295-marinedrugs-18-00005]\]; green alga *Caulerpa racemosa* bisindole alklaloid racemosin C (**286**) \[[@B296-marinedrugs-18-00005]\]; soft coral *Sarcophyton ehrenbergi* prostaglandin derivative sarcoehrendin B (**287**) \[[@B297-marinedrugs-18-00005]\]; soft coral *Sarcophyton trocheliophorum* Marenzeller diterpene sarsolilide A (**288**) \[[@B298-marinedrugs-18-00005]\]; fungus *Stachybotry* sp. HH1 ZSDS1F1-2 xanthone derivative stachybogrisephenone B (**289**) \[[@B299-marinedrugs-18-00005]\]; brown alga *Sargassum thunbergii* alkapolyene 1 (**290**) \[[@B300-marinedrugs-18-00005]\]; red alga *Palmaria palmata* mycosporine-like amino acid shinorine (**291**) \[[@B301-marinedrugs-18-00005]\]; soft coral *Sinularia* sp. cyclopentenone sinularone D (**292**) \[[@B302-marinedrugs-18-00005]\]; fungus *Stachybotrys chartarum N*-(2-benzenepropanoic acid) stachybotrylactam (**293**) \[[@B303-marinedrugs-18-00005]\]; sponge *Petrosia corticata* meroditerpenoids strongylophorine -13/-14 (**294**) \[[@B304-marinedrugs-18-00005]\]; sponge *Theonella swinhoei* steroid swinhoeisterol A (**295**) \[[@B305-marinedrugs-18-00005]\]; brown alga *Sargassum thunbergii* thunberol (**296**) \[[@B306-marinedrugs-18-00005]\]; sponge *Xestospongia vansoesti* meroterpenoid xestosaprol O (**297**) \[[@B307-marinedrugs-18-00005]\]; sponge *Monanchora pulchra* bisguanidine alkaloid urupocidin A (**298**) \[[@B308-marinedrugs-18-00005]\]; sponge *Luffariella variabilis* β-carboline alkaloid variabine B (**299**) \[[@B309-marinedrugs-18-00005]\]; and cyanobacterium *Leptolyngbya* sp. yoshinone A (**300**) \[[@B310-marinedrugs-18-00005]\].

5. Reviews on Marine Pharmacology and Pharmaceuticals {#sec5-marinedrugs-18-00005}
=====================================================

In 2014--2015, several reviews covered general and/or specific areas of marine preclinical pharmacology: (a) ***Marine pharmacology and marine pharmaceuticals:*** new marine natural products and relevant biological activities published in 2014 and 2015 \[[@B311-marinedrugs-18-00005],[@B312-marinedrugs-18-00005]\]; marine peptides, bioactivities and applications \[[@B313-marinedrugs-18-00005]\]; bioactive terpenes from marine-derived fungi \[[@B314-marinedrugs-18-00005]\]; bioactive marine natural products from actinobacteria with unique chemical structures \[[@B315-marinedrugs-18-00005]\]; Baltic cyanobacteria as a source of biologically active compounds \[[@B316-marinedrugs-18-00005]\]; biological targets of marine cyanobacteria natural products \[[@B317-marinedrugs-18-00005]\]; marine mussels as a source for bioactive compounds for human health \[[@B318-marinedrugs-18-00005]\]; pharmacological potential of cephalopod ink in drug discovery \[[@B319-marinedrugs-18-00005]\]; pharmacologically active Brazilian octocorals \[[@B320-marinedrugs-18-00005]\]; bioactive natural products isolated from marine microorganisms from Brazil \[[@B321-marinedrugs-18-00005]\]; statistical analysis of marine natural product bioactivity from 1985--2012 \[[@B322-marinedrugs-18-00005]\]; metagenomics and marine natural products drug discovery \[[@B323-marinedrugs-18-00005]\]; new horizons for selected marine natural products as drug leads \[[@B324-marinedrugs-18-00005]\]; marine-sourced agents in clinical and late preclinical development \[[@B325-marinedrugs-18-00005]\]; the global marine pharmaceutical pipeline in 2019: approved compounds and those in Phase I, II, and III of clinical development <https://www.midwestern.edu/departments/marinepharmacology.xml>. (b) ***Antimicrobial marine pharmacology****:* biophysical properties of anti-lipopolysaccharide antimicrobial peptides isolated from marine fish \[[@B326-marinedrugs-18-00005]\]; marine peptides and their anti-microbial activities \[[@B327-marinedrugs-18-00005]\]; marine membrane-active peptides as antimicrobials \[[@B328-marinedrugs-18-00005]\]; marine fungi antibacterial compounds \[[@B329-marinedrugs-18-00005]\]. (c) ***Antiviral marine pharmacology***: marine natural products with antiviral potential \[[@B330-marinedrugs-18-00005]\]; antiviral activity in marine fungi-derived natural products \[[@B331-marinedrugs-18-00005]\]. (d) ***Antiprotozoal and antimalarial marine pharmacology****:* antiprotozoal activity in marine natural products isolated from marine algae \[[@B332-marinedrugs-18-00005]\]; marine indole alkaloids as potential leads for antiprotozoal drugs \[[@B333-marinedrugs-18-00005]\]; antimalarial potency of the manzamine β-carboline alkaloids \[[@B334-marinedrugs-18-00005]\]. (e) ***Immuno- and anti-inflammatory marine pharmacology****:* marine diterpenoids as potential anti-inflammatory agents \[[@B335-marinedrugs-18-00005]\]; microalgae bioactive compounds for inflammation and cancer \[[@B336-marinedrugs-18-00005]\]. (f) ***Cardiovascular and antidiabetic marine pharmacology***: marine-derived natural products as a source of cardiovascular protective agents \[[@B337-marinedrugs-18-00005]\]; antioxidant phlorotannins derived from marine algae \[[@B338-marinedrugs-18-00005]\]; antioxidant carotenoids isolated from marine Gram-positive bacteria \[[@B339-marinedrugs-18-00005]\]; brown alga-derived fucoxanthin for diabetes therapy \[[@B340-marinedrugs-18-00005]\]; bioactive compounds from seaweed for diabetes \[[@B341-marinedrugs-18-00005]\]. (g) ***Nervous system marine pharmacology****:* astaxanthin as a potential neuroprotective agent \[[@B342-marinedrugs-18-00005]\]; origin, distribution, toxicity, and therapeutic uses of the marine neurotoxin tetrodotoxin \[[@B343-marinedrugs-18-00005]\]; marine natural products with neuroprotective activity \[[@B344-marinedrugs-18-00005]\]; marine-terpenoid gracilins as promising compounds for Alzheimer's disease \[[@B345-marinedrugs-18-00005]\]; new marine drugs for Alzheimer's disease treatment \[[@B346-marinedrugs-18-00005]\]. (h) ***Miscellaneous molecular targets and uses***: matrix metalloproteinase inhibitors isolated from edible marine algae \[[@B347-marinedrugs-18-00005]\]; marine natural products that targeting apoptosis signaling pathways \[[@B348-marinedrugs-18-00005]\]; scytonemin and emerging biomedical applications \[[@B349-marinedrugs-18-00005]\]; antiobesity effects of the carotenoid fucoxanthin \[[@B350-marinedrugs-18-00005]\]; therapeutic potential of astaxanthin \[[@B351-marinedrugs-18-00005]\]; pharmacological properties of marine coumarins \[[@B352-marinedrugs-18-00005]\].

6. Conclusions {#sec6-marinedrugs-18-00005}
==============

The current marine pharmacology 2014--2015 review is a sequel to the marine *preclinical* pharmacology pipeline review series initiated in 1998 \[[@B1-marinedrugs-18-00005],[@B2-marinedrugs-18-00005],[@B3-marinedrugs-18-00005],[@B4-marinedrugs-18-00005],[@B5-marinedrugs-18-00005],[@B6-marinedrugs-18-00005],[@B7-marinedrugs-18-00005],[@B8-marinedrugs-18-00005],[@B9-marinedrugs-18-00005]\], and consolidates the peer-reviewed preclinical marine pharmacological literature published during 2014--2015. The global preclinical marine pharmacology research involved chemists and pharmacologists from 43 countries, namely, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Cuba, Denmark, Egypt, Finland, France, French Polynesia, Germany, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Papua New Guinea, Portugal, Russian Federation, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sri Lanka, Switzerland, Taiwan, Thailand, United Kingdom, Vietnam, and the United States. Thus, during 2014--2015, the marine *preclinical* pharmaceutical pipeline continued to provide novel pharmacology that provided novel leads for the marine *clinical* pharmaceutical pipeline. As shown at the global marine pharmaceutical pipeline website, <https://www.midwestern.edu/departments/marinepharmacology.xml>, there are currently 9 approved marine-derived pharmaceuticals, and an additional 31 compounds are either in Phase I, II, and III of *clinical* pharmaceutical development.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Class             Compound/Organism ^a^                                    Chemistry                      Pharmacologic Activity                                                                           IC~50~ ^b^             MMOA ^b^                                          Country ^c^             References
  ---------------------- -------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------ ---------------------- ------------------------------------------------- ----------------------- -------------------------------------------------------------
  Antibacterial          axinellamines A and B (**1**, **2**)/sponge              Alkaloid ^f^                   Gram-positive and negative inhibition                                                            0.5--32 μg/mL ^+^      Normal cellular division inhibition               USA                     \[[@B24-marinedrugs-18-00005]\]

  Antibacterial          buanmycin (**3**)/bacterium                              Polyketide ^d^                 *S. enterica* inhibition                                                                         0.7 μM ^+^             Sortase A inhibition                              S. KOR                  \[[@B25-marinedrugs-18-00005]\]

  Antibacterial          cathelicidin (**4**)/sea snake                           Peptide ^f^                    Gram-positive and negative inhibition                                                            0.16--20.7 μg/mL ^+^   Membrane morphology alteration                    CHN                     \[[@B26-marinedrugs-18-00005]\]

  Antibacterial          clavanin A (**5**)/ascidian                              Peptide ^f^                    *S. aureus* and *E. coli* infection inhibition                                                   10 mg/kg \*\*\*        IL-6 and TNF-α inhibition                         BRA                     \[[@B27-marinedrugs-18-00005]\]

  Antibacterial          gelliusterol E (**6**)/sponge                            Terpenoid ^e^                  *C. trachomatis* inhibition                                                                      2.34 μM                OmpA protein inhibition                           EGY, GBR                \[[@B28-marinedrugs-18-00005]\]

  Antibacterial          ianthelliformisamimes B and C (**7**, **8**)/sponge      Alkaloid ^f^                   Enhanced antibiotics against *E. aerogenes, P. aeruginosa, K. Pneumoniae* MDR strains in vitro   3.12--12.5 μM \*       Enhancement of drug transporters                  FRA                     \[[@B29-marinedrugs-18-00005]\]

  Antibacterial          pardaxin (**9**)/flatfish                                Peptide ^f^                    *MR S. aureus* inhibition *in vivo*                                                              8 mg/mL \*             MCP-1, IL-6, and TNF-α inhibition                 TWN                     \[[@B30-marinedrugs-18-00005]\]

  Antibacterial          phlorofucofuroeckol-A (**10**)/alga                      Polyketide ^d^                 *MR S. aureus* inhibition                                                                        32 μg/mL ^+^           PBP2a suppresion                                  S. KOR                  \[[@B31-marinedrugs-18-00005]\]

  Antibacterial          salinamide F (**11**)/bacterium                          Peptide ^f^                    *E. coli* inhibition                                                                             0.2 μg/mL ^+^          RNAP inhibition                                   USA                     \[[@B32-marinedrugs-18-00005]\]

  Antibacterial          piscidins (**12**, **13**)/fish                          Peptide ^f^                    *K. pneumonia* and *A. baumannii* inhibition *in vitro*                                          1.5--3.1 μM ^+^        Undetermined                                      TWN                     \[[@B33-marinedrugs-18-00005]\]

  Antibacterial          adametizine A (**14**)/fungus                            Terpenoid ^e^                  *S. aureus* inhibition                                                                           8 μg/mL ^+^            Undetermined                                      CHN                     \[[@B34-marinedrugs-18-00005]\]

  Antibacterial          agelamadins A and B (**15**, **16**)/sponge              Alkaloid ^f^                   *M. luteus* and *C. neoformans* inhibition                                                       5--8 μg/mL ^+^         Undetermined                                      AUS, JPN                \[[@B35-marinedrugs-18-00005]\]

  Antibacterial          *Aspergillus* sp. butyrolactone (**17**)/fungus          Terpenoid ^e^                  *S. aureus* and *B. cereus* inhibition                                                           1.56 μM ^+^            Undetermined                                      CHN                     \[[@B36-marinedrugs-18-00005]\]

  Antibacterial          aszonapyrone A (**18**)/fungus                           Terpenoid ^e^                  *S. aureus* and *B. subtilis* inhibition                                                         8 μg/mL ^+^            Undetermined                                      PRT, THAI               \[[@B37-marinedrugs-18-00005]\]

  Antibacterial          austalide R (**19**)/fungus                              Terpenoid ^e^                  Marine bacteria inhibition                                                                       0.1 μg/mL ^+^          Undetermined                                      CHN, DEU, GBR           \[[@B38-marinedrugs-18-00005]\]

  Antibacterial          citrifelin B (**20**)/fungus                             Polyketide ^d^                 *S. aureus* inhibition                                                                           4 μg/mL ^+^            Undetermined                                      CHN                     \[[@B39-marinedrugs-18-00005]\]

  Antibacterial          desmethylisaridin C1 (**21**)/fungus                     Peptide ^f^                    *E. coli* inhibition                                                                             8 μg/mL                Undetermined                                      CHN                     \[[@B40-marinedrugs-18-00005]\]

  Antibacterial          *D. granulosa* diphenyl ethers (**22**, **23**)/sponge   Polyketide ^d^                 Gram-positive and negative inhibition                                                            1--16 μg/mL ^+^        Undetermined                                      USA                     \[[@B41-marinedrugs-18-00005]\]

  Antibacterial          diaporthalasin (**24**) /fungus                          Terpenoid ^e^                  MR *S. aureus* inhibition                                                                        2 μg/mL ^+^            Undetermined                                      THAI                    \[[@B42-marinedrugs-18-00005]\]

  Antibacterial          *D. pulchra* furanones (**25**, **26**)/alga             Alkaloid ^f^                   *P. aeruginosa* biofilm inhibition                                                               1.3 μM ^+^             Undetermined                                      BRA, FRA, USA           \[[@B43-marinedrugs-18-00005]\]

  Antibacterial          aureol B (**27**)/ sponge                                Terpenoid ^e^                  Gram-positive and negative inhibition                                                            1 μg/mL ^+^            Undetermined                                      S. KOR                  \[[@B44-marinedrugs-18-00005]\]

  Antibacterial          dysidinoid A (**28**)/sponge                             Terpenoid ^e^                  MR *S. aureus* inhibition                                                                        8 μg/mL \*\*           Undetermined                                      CHN                     \[[@B45-marinedrugs-18-00005]\]

  Antibacterial          *Eunicea* sp. compounds (**29**, **30**)/sponge          Terpenoid ^e^                  *P. aeruginosa* and *S. aureus* biofilm inhibition                                               0.5 mg/mL ^+^          Undetermined                                      COL                     \[[@B46-marinedrugs-18-00005]\]

  Antibacterial          flavipesin A (**31**)/fungus                             Polyketide ^d^                 *S. aureus* and *B. subtillis* inhibition                                                        0.25--8 μg/mL ^+^      Undetermined                                      CHN                     \[[@B47-marinedrugs-18-00005]\]

  Antibacterial          gageopeptides A--D (**32--35**)/bacterium                Peptide ^f^                    *S. aureus* and *B. subtillis* inhibition                                                        0.04--0.08 μM ^+^      Undetermined                                      BGD, S. KOR             \[[@B48-marinedrugs-18-00005]\]

  Antibacterial          gageotetrins A--C (**36--38**)/bacterium                 Peptide ^f^                    *S. aureus* and *B. subtillis* inhibition                                                        0.02--0.04 μM ^+^      Undetermined                                      BGD, S. KOR             \[[@B49-marinedrugs-18-00005]\]

  Antibacterial          hormaomycin B (**39**)/bacterium                         Peptide ^f^                    *S. aureus* and *K. rhizophila* inhibition                                                       0.4--7 μM ^+^          Undetermined                                      S. KOR                  \[[@B50-marinedrugs-18-00005]\]

  Antibacterial          ieodoglucomide C (**40**)/bacterium                      Glycolipid                     Gram-positive and negative inhibition                                                            0.01--0.05 μM ^+^      Undetermined                                      S. KOR                  \[[@B51-marinedrugs-18-00005]\]

  Antibacterial          isoikarugamycin (**41**)/bacterium                       Alkaloid ^f^/ Terpenoid ^e^    MR *S.aureus*                                                                                    2--4 μg/mL ^+^         Undetermined                                      ESP                     \[[@B52-marinedrugs-18-00005]\]

  Antibacterial          keramadine (**42**)/sponge                               Alkaloid ^f^                   *M. luteus* inhibition                                                                           4 μg/mL ^+^            Undetermined                                      AUS, JPN                \[[@B53-marinedrugs-18-00005]\]

  Antibacterial          *Ircinia* sp. secosterols (**43**, **44**)/sponge        Terpenoid ^e^                  *M. luteus* and *S. epidermidis* inhibition                                                      3.1, 6.3 μg/mL         Undetermined                                      S. KOR                  \[[@B54-marinedrugs-18-00005],[@B55-marinedrugs-18-00005]\]

  Antibacterial          *L. dendyi* terpenoids (**45**, **46**)/sponge           Polyketide ^d^                 MR *S. aureus* inhibition                                                                        0.05--0.29 μM          Undetermined                                      USA                     \[[@B56-marinedrugs-18-00005]\]

  Antibacterial          lindgomycin (**47**)/fungus                              Polyketide ^d^                 MR *S. aureus* inhibition                                                                        5.1 μM                 Undetermined                                      CHN, DEU                \[[@B57-marinedrugs-18-00005]\]

  Antibacterial          marformysin D (**48**)/bacterium                         Peptide ^f^                    *M. luteus* inhibition                                                                           0.063 μg/mL ^+^        Undetermined                                      CHN                     \[[@B58-marinedrugs-18-00005]\]

  Antibacterial          mollemycin A (**49**)/bacterium                          Polyketide ^d^                 *S. aureus and S. epidermidis* inhibition                                                        0.05 μM                Undetermined                                      AUS                     \[[@B59-marinedrugs-18-00005]\]

  Antibacterial          neolaurene (**50**)/alga                                 Terpenoid ^e^                  *S. typhi* and *S. aureus* inhibition                                                            7.5 μg/mL              Undetermined                                      MYS                     \[[@B60-marinedrugs-18-00005]\]

  Antibacterial          penicyclone A (**51**)/fungus                            Polyketide ^d^                 *S. aureus* inhibition                                                                           0.3 μg/mL ^+^          Undetermined                                      CHN                     \[[@B61-marinedrugs-18-00005]\]

  Antibacterial          *P. oxalicum* enamide (**52**)/fungus                    Polyketide ^d^                 *S. aureus* inhibition                                                                           2 μg/mL ^+^            Undetermined                                      CHN                     \[[@B62-marinedrugs-18-00005]\]

  Antibacterial          puupehenol (**53**)/ sponge                              Terpenoid ^e^                  *B. cereus* and *S. aureus* inhibition                                                           10 μg/disk ^+^         Undetermined                                      AUS, USA                \[[@B63-marinedrugs-18-00005]\]

  Antibacterial          phyllospongin E (**54**)/sponge                          Terpenoid ^e^                  *B. cereus* and *S. aureus* inhibition                                                           2.5--3.3 μg/mL ^+^     Undetermined                                      EGY, GBR                \[[@B64-marinedrugs-18-00005]\]

  Antibacterial          sarcotrocheliols (**55**, **56**)/soft coral             Terpenoid ^e^                  MR *S. aureus* inhibition                                                                        1.5--4.3 μM ^+^        Undetermined                                      SAU                     \[[@B65-marinedrugs-18-00005]\]

  Antibacterial          spiromastixone J (**57**)/fungus                         Polyketide ^d^                 MR *S. aureus* inhibition                                                                        2 μM                   Undetermined                                      CHN, DEU                \[[@B66-marinedrugs-18-00005]\]

  Antibacterial          stachyin B (**58**)/fungus                               Alkaloid ^f^ /Terpenoid ^e^    MR *S. aureus* and *B. subtillis* inhibition                                                     1.4--1.7 μM            Undetermined                                      CHN, DEU                \[[@B67-marinedrugs-18-00005]\]

  Antibacterial          *Streptomyces* sp. glycoside (**59**)/bacterium          Polyketide ^d^                 *C. trachomatis* inhibition                                                                      4.03 μM                Undetermined                                      EGY, DEU                \[[@B68-marinedrugs-18-00005]\]

  Antibacterial          subergosterones A--C (**60--62**)/gorgonian coral        Terpenoid ^e^                  *B. cereus* inhibition                                                                           1.6--3.1 μM ^+^        Undetermined                                      CHN                     \[[@B69-marinedrugs-18-00005]\]

  Antibacterial          vitroprocine A (**63**)/bacterium                        Polyketide ^d^                 *A. baumannii* inhibition                                                                        8 μg/mL ^+^            Undetermined                                      TWN, USA                \[[@B70-marinedrugs-18-00005]\]

  Antibacterial          xestospongiamide (**64**)/sponge                         Polyketide ^d^                 Gram-positive and negative inhibition                                                            2.5 μM ^+^             Undetermined                                      EGY, SAU                \[[@B71-marinedrugs-18-00005]\]

  **Antifungal**         bahamaolide A (**65**)/bacterium                         Polyketide ^d^                 *C. albicans* inhibition                                                                         1.5--3.1 μg/mL ^+^     ICL inhibition                                    S. KOR                  \[[@B72-marinedrugs-18-00005]\]

  Antifungal             heronamide C (**66**)/bacterium                          Polyketal/\                    *S. pombe* cell inhibition                                                                       5.8 μM ^+^             Alteration of membrane microdomains               JPN                     \[[@B73-marinedrugs-18-00005]\]
                                                                                  alkaloid ^f^                                                                                                                                                                                                                     

  Antifungal             forazoline A (**67**)/bacterium                          Polyketide ^d^                 *C. albicans* inhibition                                                                         16 μg/mL ^+^           Affected membrane integrity                       USA                     \[[@B74-marinedrugs-18-00005]\]

  Antifungal             aaptamine derivative (**68**)/sponge                     Alkaloid ^f^                   *T. rubrum* inhibition                                                                           4 μg/mL ^+^            Undetermined                                      CHN                     \[[@B75-marinedrugs-18-00005]\]

  Antifungal             amphidinin G (**69**)/dinoflagellate                     Polyketide ^d^                 *T. mentagrophytes* inhibition                                                                   8 μg/mL                Undetermined                                      JPN                     \[[@B76-marinedrugs-18-00005]\]

  Antifungal             amphidinol 18 (**70**)/dinoflagellate                    Polyketide ^d^                 *C. albicans* inhibition                                                                         9 μg/mL ^+^            Undetermined                                      ITA                     \[[@B77-marinedrugs-18-00005]\]

  Antifungal             crambescin homologues (**71--73**)/sponge                Alkaloid ^f^                   *C. neoformans* var. *gattii* inhibition                                                         0.85--2.6 μM ^+^       Undetermined                                      USA                     \[[@B78-marinedrugs-18-00005]\]

  Antifungal             coustesides C and D (**74**, **75**)/sea cucumber        Terpenoid glycoside ^e^        *C. albicans* inhibition                                                                         1 mg/mL ^++^           Undetermined                                      EGY, S.KOR              \[[@B79-marinedrugs-18-00005]\]

  Antifungal             *L. okamurai* laurenes (**76--78**)/alga                 Terpenoid ^e^                  *C. glabrata* inhibition                                                                         2--4 μg/mL \*\*        Undetermined                                      CHN                     \[[@B80-marinedrugs-18-00005],[@B81-marinedrugs-18-00005]\]

  Antifungal             mohangamide A (**79**)/bacterium                         Peptide ^f^                    *C. albicans* isocitrate lyase inhibition                                                        4.4 μM                 Undetermined                                      S. KOR                  \[[@B82-marinedrugs-18-00005]\]

  Antifungal             pleosporallin E (**80**)/fungus                          Polyketide ^d^                 *C. albicans* inhibition                                                                         7.44 μg/mL ^+^         Undetermined                                      CHN                     \[[@B83-marinedrugs-18-00005]\]

  Antifungal             *S. purpurea* lysophospholipid (**81**)/sponge           Phospholipid                   *C. glabrata* and *C. neoformans* inhibition                                                     4 μg/mL ^+^            Undetermined                                      CHN                     \[[@B84-marinedrugs-18-00005]\]

  Antifungal             taurospongin A (**82**)/sponge                           Polyketide ^d^                 *C. neoformans* inhibition                                                                       1 μg/mL ^+^            Undetermined                                      AUS, JPN                \[[@B85-marinedrugs-18-00005]\]

  Antifungal             variegatuside D (**83**)/sea cucumber                    Terpenoid glycoside ^e^        Several *Candida* species inhibition                                                             3.4--13.6 μg/mL ^+^    Undetermined                                      CHN                     \[[@B86-marinedrugs-18-00005]\]

  Antifungal             xestospongiamide (**64**)/sponge                         Polyketide ^d^                 *A. niger* and *C. albicans* inhibition                                                          \>5 μM ^+^             Undetermined                                      EGY, SAU                \[[@B71-marinedrugs-18-00005]\]

  **Antimalarial**       *C. hooperi* isonitrile (**84**)/sponge                  Terpenoid ^e^                  *P. falciparum* D6 and W2 strain inhibition                                                      4.3--4.7 nM            β-hematin inhibition                              USA, ZAF                \[[@B87-marinedrugs-18-00005]\]

  Antimalarial           actinoramide A (**85**)/bacterium                        Peptide ^f^                    *P. falciparum* strains inhibition                                                               0.2 μM                 Undetermined                                      CRI, USA                \[[@B88-marinedrugs-18-00005]\]

  Antimalarial           diacarperoxide J (**86**)/sponge                         Terpenoid ^e^                  *P. falciparum* D6 and W2 strain inhibition                                                      1.6--1.8 μM            Undetermined                                      CHN, USA                \[[@B89-marinedrugs-18-00005]\]

  Antimalarial           laevigatol A (**87**)/soft coral                         Terpenoid ^e^                  *P. falciparum* NF54 strain inhibition                                                           3.0 μM                 Undetermined                                      CHE, DEU, S. KOR, VNM   \[[@B90-marinedrugs-18-00005]\]

  Antimalarial           mollemycin A (**49**)/bacterium                          Polyketide ^d^                 *P. falciparum* 3D7and Dd2 strain inhibition                                                     7--9 nM                Undetermined                                      AUS                     \[[@B59-marinedrugs-18-00005]\]

  Antimalarial           mon amphilectines B and C (**88**, **89**)/sponge        Terpenoid ^e^                  *P. falciparum* 3D7strain inhibition                                                             44 nM                  Undetermined                                      USA                     \[[@B91-marinedrugs-18-00005]\]

  Antimalarial           netamine K (**90**)/sponge                               Alkaloid ^f^                   *P. falciparum* inhibition                                                                       2.4 μM                 Undetermined                                      BEL, FRA, ISR           \[[@B92-marinedrugs-18-00005]\]

  Antimalarial           *P. ocellata* sesquiterpenes (**91--93**)/nudibranch     Terpenoid ^e^                  *P. falciparum* inhibition                                                                       0.26--0.3 μM           Undetermined                                      AUS, ITA                \[[@B93-marinedrugs-18-00005]\]

  Antimalarial           *P. simplex* polyketide (**94**)/sponge                  Polyketide ^d^                 *P. falciparum* D10 and W2 strain inhibition                                                     2.7--4.0 μM            Undetermined                                      CHN, ITA                \[[@B94-marinedrugs-18-00005]\]

  **Antiprotozoal**      plakortide E (**95**)/sponge                             Polyketide ^d^                 *T. brucei* inhibition                                                                           5 μM                   Rhodesain inhibition                              EGY, DEU                \[[@B95-marinedrugs-18-00005]\]

  Antiprotozoal          batzelladine L (**96**)/sponge                           Alkaloid ^f^                   *T. cruzi* and *L. infantum* inhibition                                                          2 μM                   Enhanced ROS generation                           BRA, CAN                \[[@B96-marinedrugs-18-00005]\]

  Antiprotozoal          actinoporin A (**97**)/ bacterium                        Polyketide ^d^                 *T. b. brucei* inhibition                                                                        15 μM                  Undetermined                                      AUS, DEU, EGY, GBR      \[[@B97-marinedrugs-18-00005]\]

  Antiprotozoal          astropectenol A (**98**)/soft coral                      Terpenoid ^e^                  *T. brucei* inhibition                                                                           1.6 μM                 Undetermined                                      DEU, VNM, S. KOR        \[[@B98-marinedrugs-18-00005]\]

  Antiprotozoal          *H. simulans* sterol (**99**) sponge                     Terpenoid ^e^                  *T. b. brucei* inhibition                                                                        4.6 μM ^+^             Undetermined                                      IRL, GBR                \[[@B99-marinedrugs-18-00005]\]

  Antiprotozoal          lobosamide A (**100**)/bacterium                         Alkaloid ^f^                   *T. b. brucei* inhibition                                                                        0.8 μM                 Undetermined                                      USA                     \[[@B100-marinedrugs-18-00005]\]

  Antiprotozoal          lobocrasols A and C (**101**, **102**)/soft corals       Terpenoid ^e^                  *L. donovani* inhibition                                                                         0.18 μM                Undetermined                                      CHE, DEU, S. KOR, VNM   \[[@B90-marinedrugs-18-00005]\]

  Antiprotozoal          mangromicin A (**103**)/fungus                           Polyketide ^d^                 *T. b. brucei* inhibition                                                                        2.44 µg/mL             Undetermined                                      JPN                     \[[@B101-marinedrugs-18-00005]\]

  Antiprotozoal          crassumols D and E (**104**, **105**)/soft corals        Terpenoid ^e^                  *T. b. rhodesiense* inhibition                                                                   0.61 and 0.72 μM       Undetermined                                      CHE, DEU, S. KOR, VNM   \[[@B90-marinedrugs-18-00005]\]

  Antiprotozoal          sesterstamide (**106**)/sponge                           Terpenoid ^e^                  *L. donovani* inhibition                                                                         32.9 µg/mL             Undetermined                                      CHN                     \[[@B102-marinedrugs-18-00005]\]

  Antiprotozoal          shagene A (**107**)/soft coral                           Terpenoid ^e^                  *L. donovani* inhibition                                                                         5 μM                   Undetermined                                      AUS, USA                \[[@B103-marinedrugs-18-00005]\]

  **Antituberculosis**   aaptamine analog (**108**)/sponge                        Alkaloid ^f^                   *M. smegmatis* inhibition                                                                        6.25 μg/mL ^+^         Undetermined                                      JPN                     \[[@B104-marinedrugs-18-00005]\]

  Antituberculosis       callyaerins A and B (**109**, **110**)/sponge            Peptide ^f^                    *M. tuberculosis* inhibition                                                                     2, 5 μM \*\*           Undetermined                                      CHN, DEU, NLD           \[[@B105-marinedrugs-18-00005]\]

  Antituberculosis       denigrin C (**111**)/sponge                              Alkaloid ^f^                   *M. tuberculosis* H~37~Rv inhibition                                                             4 μg/mL ^+^            Undetermined                                      IND                     \[[@B106-marinedrugs-18-00005]\]

  Antituberculosis       oxazinin A (**112**)/fungus                              Polyketide ^d^                 *M. tuberculosis* inhibition                                                                     2.9 μM                 Undetermined                                      USA                     \[[@B107-marinedrugs-18-00005]\]

  **Antiviral**          pateamine A (**113**)/sponge                             Mixed Biogenesis               Sindbis virus mRNA translation inhibition                                                        \>100 nM               nsP1 or nsP2 viral protein synthesis inhibition   CAN, ESP, NZL           \[[@B108-marinedrugs-18-00005]\]

  Antiviral              abyssomicin 2 (**114**)/bacterium                        Polyketide ^d^                 HIV-1 reactivation                                                                               13.9 μM                Increased viral RNA in CD4^+^ T cells             USA                     \[[@B109-marinedrugs-18-00005]\]

  Antiviral              8,4′''-dieckol (**115**)/alga                            Polyketide ^d^                 HIV-1 inhibition                                                                                 10 μM \*               Reverse transcriptase inhibition                  S. KOR                  \[[@B110-marinedrugs-18-00005]\]

  Antiviral              truncateol M (**116**)/fungus                            Terpenoid ^e^                  H1N1 influenza A virus inhibition                                                                8.8 μM                 Virion assembly/release inhibition                CHN, DEU                \[[@B111-marinedrugs-18-00005]\]

  Antiviral              neoechinulin B (**117**)/fungus                          Alkaloid ^f^                   H3N2, H1N1 A influenza virus inhibition                                                          17-22 μM               Hemagglutinin inhibition                          CHN, DEU                \[[@B112-marinedrugs-18-00005]\]

  Antiviral              thaixylomolin I (**118**)/mangrove                       Terpenoid ^e^                  H1N1 influenza A virus inhibition                                                                77 μM                  Undetermined                                      CHN, DEU, THAI          \[[@B113-marinedrugs-18-00005]\]

  Antiviral              aaptamine derivative (**68**)/sponge                     Alkaloid ^f^                   HIV-1 inhibition                                                                                 10 μM \*               Undetermined                                      CHN                     \[[@B75-marinedrugs-18-00005]\]

  Antiviral              aflaquinolone B derivative (**119**)/fungus              Mixed biogenesis               RSV inhibition                                                                                   0.042 μM               Undetermined                                      CHN                     \[[@B114-marinedrugs-18-00005]\]

  Antiviral              *A. terreus* lactones (**120**, **121**)/fungus          Polyketide ^d^                 HSV-1 inhibition                                                                                 6.34 μg/mL             Undetermined                                      CHN                     \[[@B115-marinedrugs-18-00005]\]

  Antiviral              chartarutine B (**122**)/fungus                          Alkaloid ^f^/terpenoid ^e^     HIV-1 inhibition                                                                                 4.9 μM                 Undetermined                                      CHN, DEU                \[[@B116-marinedrugs-18-00005]\]

  Antiviral              debromoaplysiatoxin (**123**)/cyanobacterium             Polyketide ^d^                 CHIKV inhibition                                                                                 1.4 μM                 Undetermined                                      NZL, SGP                \[[@B117-marinedrugs-18-00005]\]

  Antiviral              dolabelladienol A (**124**)/alga                         Terpenoid ^e^                  HIV-1 inhibition                                                                                 2.9 μM                 Undetermined                                      BRA, COL, ESP           \[[@B118-marinedrugs-18-00005]\]

  Antiviral              *D. plectens* diterpene (**125**)/alga                   Terpenoid ^e^                  HIV-1 inhibition                                                                                 16.1 μM                Undetermined                                      CHN                     \[[@B119-marinedrugs-18-00005]\]

  Antiviral              *Dysidea* sp. PBDEs (**22**, **23**)/sponge              Polyketide ^d^                 Hepatitis B inhibition                                                                           0.23--0.80 μM          Core promoter inhibition                          IDN, JPN, NLD           \[[@B120-marinedrugs-18-00005]\]

  Antiviral              echrebsteroid C (**126**)/gorgonian                      Terpenoid ^e^                  RSV inhibition                                                                                   0.19 μM                Undetermined                                      CHN                     \[[@B121-marinedrugs-18-00005]\]

  Antiviral              (+)-pestaloxazine A (**127**)/fungus                     Alkaloid ^f^                   Enterovirus 71 inhibition                                                                        14.2 μM                Undetermined                                      CHN                     \[[@B122-marinedrugs-18-00005]\]

  Antiviral              phlorofucofuroeckol-A(**10**)/alga                       Polyketide ^d^                 MNV inhibition                                                                                   0.9 μM                 Undetermined                                      S. KOR                  \[[@B123-marinedrugs-18-00005]\]

  Antiviral              secocrassumol (**128**)/soft coral                       Terpenoid ^e^                  HCMV inhibition                                                                                  5 μg/mL                Undetermined                                      TWN                     \[[@B124-marinedrugs-18-00005]\]

  Antiviral              sporolide B (**129**)/bacterium                          Polyketide ^d^                 HIV-reverse transcriptase inhibition                                                             14 μM                  Undetermined                                      IND                     \[[@B125-marinedrugs-18-00005]\]

  Antiviral              stellettapeptins A and B (**130**, **131**)/sponge       Peptide ^f^                    HIV-1 infection inhibition                                                                       23--27 nM              Undetermined                                      USA                     \[[@B126-marinedrugs-18-00005]\]

  Antiviral              trichobotrysin A (**132**)/fungus                        Polyketide ^d^ /Alkaloid ^f^   HSV-1 inhibition                                                                                 3.08 μM                Undetermined                                      CHN                     \[[@B127-marinedrugs-18-00005]\]

  **Anthelmintic**       phorioadenine A (**133**)/sponge                         Alkaloid ^f^                   *H. contortus* inhibition                                                                        31 μg/mL ^+++^         Undetermined                                      AUS                     \[[@B128-marinedrugs-18-00005]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**^a^ Organism**: *Kingdom Animalia*: ascidian, flatfish, sea snakes (Phylum Chordata), gorgonian, coral (Phylum Cnidaria), sea cucumber (Phylum Echinodermata), nudibranch (Phylum Mollusca), sponge (Phylum Porifera); *Kingdom Monera*: bacterium (Phylum Cyanobacteria); *Kingdom Fungi*: fungus; *Kingdom Plantae:* alga, mangrove, seagrass; *Kingdom Protista*: dinoflagellates; **^b^ IC~50~**: concentration of a compound required for 50% inhibition in vitro, \*: estimated IC~50~, \*\*: MIC~80~, MIC~90~, or IC~90~, \*\*\*: in vivo study; ^+^ MIC: minimum inhibitory concentration, ^++^ MID: minimum inhibitory concentration per disk; ^+++^ LC~90~: concentration of a compound required for 90% lethality; **^b^ MMOA**: molecular mechanism of action; **^c^ Country**: AUS: Australia; BEL: Belgium; BGD: Bangladesh; BRA: Brazil; CAN: Canada; CHE: Switzerland; CHN: China; COL: Colombia; CRI: Costa Rica; DEU: Germany; EGY: Egypt; ESP: Spain; FRA: France; GBR: United Kingdom; IDN: Indonesia; IND: India; IRL: Ireland; ISR: Israel; ITA: Italy; JPN: Japan; MYS: Malaysia; NLD: The Netherlands; NZL: New Zealand; PRT: Portugal; SAU: Saudi Arabia; SGP: Singapore; S. KOR: South Korea; THAI: Thailand; TWN: Taiwan; VNM: Vietnam; ZAF: S. Africa; **Chemistry: ^d^** polyketide; **^e^** terpene; **^f^** nitrogen-containing compound; **^g^** polysaccharide; **^h^** shikimate; **Abbreviations:** CHIKV: chikungunya virus; HCMV: human cytomegalovirus; MNV: murine norovirus; HSV: herpes simplex virus; ICL: isocitrate lyase; MR: methicillin-resistant; PBP2a: penicillin-binding protein 2a; RNAP: RNA-polymerase; RSV: respiratory syncytial virus; TNF-α: tumor necrosis factor α.
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###### 

Marine pharmacology in 2014--2015: marine compounds with antidiabetic and anti-inflammatory activity, and affecting the immune and nervous system.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Class           Compound/Organism ^a+^                                  Chemistry                      Pharmacological Activity                             IC~50~ ^b^        MMOA ^c^                                          Country ^d^                    References
  -------------------- ------------------------------------------------------- ------------------------------ ---------------------------------------------------- ----------------- ------------------------------------------------- ------------------------------ ---------------------------------------------------------------
  Antidiabetic         fucoxanthin and fucoxanthinol (**134**, **135**)/alga   Terpenoid ^f^                  Improved glucose tolerance in vitro and in vivo      50 µM \*          Cytokine inhibition                               JPN, S. KOR                    \[[@B154-marinedrugs-18-00005],[@B155-marinedrugs-18-00005]\]

  Antidiabetic         octaphlorethol A (**136**)/alga                         Shikimate ^h^                  α-glucosidase inhibition                             110 µM            Molecular docking on active site                  CAN, S. KOR                    \[[@B156-marinedrugs-18-00005]\]

  Antidiabetic         phlorofucofuroeckol-A (**10**)/alga                     Polyketide ^d^                 Decreased glucose levels in vivo                     10 mg/kg \*\*     α-glucosidase inhibition                          S. KOR                         \[[@B157-marinedrugs-18-00005]\]

  Antidiabetic         Con-Ins G1 (**137**)/cone snail                         Peptide ^g^                    Hypoglycemia induction                               65 ng/g \*        Undetermined                                      AUS, DNK, USA                  \[[@B158-marinedrugs-18-00005]\]

  Antidiabetic         dehydroeuryspongin A (**138**)/sponge                   Terpenoid ^f^                  PTP1B inhibition                                     3.58 μM           Undetermined                                      IDN, JPN                       \[[@B159-marinedrugs-18-00005]\]

  Antidiabetic         *Epicoccum* sp. diterpene (**139**)/fungus              Terpenoid ^f^                  α-glucosidase inhibition                             4.6 μM            Undetermined                                      CHN                            \[[@B160-marinedrugs-18-00005]\]

  Antidiabetic         suncheonoside A (**140**)/bacterium                     Terpenoid ^f^                  Adiponectin production                               10 μM \*          Undetermined                                      S. KOR                         \[[@B161-marinedrugs-18-00005]\]

  Antidiabetic         terrelumamide A (**141**)/fungus                        Peptide ^g^                    Adiponectin production                               37 μM \*          Undetermined                                      S. KOR                         \[[@B162-marinedrugs-18-00005]\]

  Antidiabetic         *X. testudinaria* lipid (**142**)/sponge                Polyketide ^d^                 PTP1B inhibition                                     5.3 μM            Undetermined                                      CHN                            \[[@B163-marinedrugs-18-00005]\]

  Anti-inflammatory    alcyonolide congeners (**143**, **144**)/soft coral     Terpenoid ^f^                  Macrophage NO inhibition                             2 μM \*           iNOS expression inhibition                        JPN                            \[[@B164-marinedrugs-18-00005]\]

  Anti-inflammatory    astaxanthin (**145**)/alga                              Terpenoid ^f^                  Oxidative stress inhibition in vivo                  10 mg/kg \*\*     CAT and SOD enhancement                           CHN                            \[[@B165-marinedrugs-18-00005]\]

  Anti-inflammatory    8,8′-bieckol (**146**)/alga                             Polyketide ^e^                 Macrophage NO and PGE~2~ release inhibition          50 μM \*          Inhibition of NFκB                                S. KOR                         \[[@B166-marinedrugs-18-00005]\]

  Anti-inflammatory    convolutamydine A (**147**)/ bryozoa                    Alkaloid ^g^                   Formalin-induced licking behavior inhibition         0.01 mg/kg \*     TNF-α, IL-6 release inhibition                    BRA                            \[[@B167-marinedrugs-18-00005]\]

  Anti-inflammatory    capgermacrene A (**148**)/ soft coral                   Terpenoid ^f^                  Macrophage NO and IL-1β inhibition                   \<10 μg/mL \*     iNOS expression inhibition                        MYS, S. KOR                    \[[@B168-marinedrugs-18-00005]\]

  Anti-inflammatory    cathelicidin (**4**)/sea snake                          Peptide ^g^                    Binding of LPS to TLR4 inhibition                    4 μg/mL \*        Inflammatory cytokine inhibition                  CHN                            \[[@B26-marinedrugs-18-00005]\]

  Anti-inflammatory    dactyloditerpenol acetate (**149**)/ sea hare           Terpenoid ^f^                  LPS- activated microglia in vitro inhibition         0.4--1 μM         O~2~^-^ and TXB~2~ inhibition                     USA                            \[[@B169-marinedrugs-18-00005]\]

  Anti-inflammatory    dieckol (**150**)/alga                                  Shikimate ^h^                  Macrophage iNOS transcription inhibition             30 μM \*          Inhibition of NFκB and p38MAPK                    S. KOR                         \[[@B170-marinedrugs-18-00005]\]

  Anti-inflammatory    dieckol (**150**)/alga                                  Shikimate ^h^                  Human keratinocyte MDC/CCL22 inhibition              12.5 μM \*        STAT1 phosphorylation inhibition                  S. KOR                         \[[@B171-marinedrugs-18-00005]\]

  Anti-inflammatory    excavatolide B (**151**)/gorgonian                      Terpenoid ^f^                  Macrophage iNOS and COX-2 transcription inhibition   25 μM \*          In vivo iNOS protein expression reduction         TWN                            \[[@B172-marinedrugs-18-00005]\]

  Anti-inflammatory    flexibilide (**152**)/soft coral                        Terpenoid ^f^                  Neuropathic pain inhibition                          10 µg \*          Upregulation of TGF-β1                            TWN                            \[[@B173-marinedrugs-18-00005]\]

  Anti-inflammatory    fucoxanthinol (**135**)/alga                            Terpenoid ^f^                  Macrophage TNF-α and MCP-1 release inhibition        10 μM             COX-2 expression inhibition                       JPN                            \[[@B155-marinedrugs-18-00005]\]

  Anti-inflammatory    *H. fusiforme* flavone (**153**)/ alga                  Shikimate ^h^/Polyketide ^d^   Macrophage NO and PGE~2~ release inhibition          10 μg/mL \*       iNOS, COX-2 expression inhibition                 S. KOR                         \[[@B174-marinedrugs-18-00005]\]

  Anti-inflammatory    5β-hydroxypalisadin B (**154**)/alga                    Terpenoid ^f^                  Macrophage NO release inhibition                     17 μM             Partial iNOS expression inhibition                LKA, MYS, S. KOR               \[[@B175-marinedrugs-18-00005]\]

  Anti-inflammatory    glaucumolides A and B (**155**, **156**)/soft coral     Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               2.8--4 µM \*      iNOS, COX-2 inhibition                            TWN                            \[[@B176-marinedrugs-18-00005]\]

  Anti-inflammatory    phlorofucofuroeckol-B (**157**)/alga                    Polyketide ^d^                 Microglia activation inhibition                      0.1 μg/mL \*      iNOS, COX-2 inhibition                            S. KOR                         \[[@B177-marinedrugs-18-00005]\]

  Anti-inflammatory    *P. palmata* lipid (**158**)/alga                       Polyketide ^d^                 Macrophage NO release inhibition                     16.7 μM           iNOS expression inhibition                        CAN                            \[[@B178-marinedrugs-18-00005]\]

  Anti-inflammatory    reduced scytonemin (**159**)/alga                       Alkaloid ^g^                   Macrophage NO release inhibition                     1 µM \*           HO-1 expression induction                         JPN                            \[[@B179-marinedrugs-18-00005]\]

  Anti-inflammatory    sinuleptolide (**160**)/soft coral                      Terpenoid ^f^                  LPS-activated rat microglia in vitro inhibition      0.5--2.9 μM       Cytokine release inhibition                       ESP, FIN, IND, ITA,            \[[@B180-marinedrugs-18-00005]\]

  Anti-inflammatory    sarcopanol A (**161**)/soft coral                       Terpenoid ^f^                  iNOS, COX-2, and ICAM-1 transcription inhibition     8.3 µM            NFκB inhibition                                   S. KOR, VNM                    \[[@B181-marinedrugs-18-00005]\]

  Anti-inflammatory    sinumaximol H (**162**)/sponge                          Terpenoid ^f^                  iNOS and ICAM-1 transcription inhibition             1 µM \*           NFκB inhibition                                   S. KOR, VNM                    \[[@B182-marinedrugs-18-00005]\]

  Anti-inflammatory    tanzawaic acid A (**163**)/fungus                       Polyketide ^d^                 NO inhibition                                        7.1 µM            iNOS and PTP1B inhibition                         VNM, S. KOR                    \[[@B183-marinedrugs-18-00005]\]

  Anti-inflammatory    aspertetranone D (**164**)/fungus                       Terpenoid ^f^                  IL-6 inhibition                                      40 µM \*          Undetermined                                      CHN, USA                       \[[@B184-marinedrugs-18-00005]\]

  Anti-inflammatory    briarenolide J (**165**)/soft coral                     Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               10--15 µM         Undetermined                                      TWN                            \[[@B185-marinedrugs-18-00005]\]

  Anti-inflammatory    briarenolides K and L (**166**, **167**)/soft coral     Terpenoid ^f^                  Macrophage iNOS inhibition                           \>10 μg/mL \*     Undetermined                                      TWN                            \[[@B186-marinedrugs-18-00005]\]

  Anti-inflammatory    briarenolides U, V, W (**168**, **169**)/soft coral     Terpenoid ^f^                  Macrophage COX-2 and iNOS expression inhibition      \>10 μg/mL \*     Undetermined                                      TWN                            \[[@B187-marinedrugs-18-00005]\]

  Anti-inflammatory    briaviolides E and I (**170**, **171**)/soft coral      Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               \>10 μg/mL \*     Undetermined                                      TWN                            \[[@B188-marinedrugs-18-00005]\]

  Anti-inflammatory    dermacozine H (**172**)/bacterium                       Alkaloid ^g^                   Radical scavenging activity                          18.8 µM           Undetermined                                      DEU, EGY, UK                   \[[@B189-marinedrugs-18-00005]\]

  Anti-inflammatory    dysifragilone A (**173**)/sponge                        Terpenoid ^f^                  Macrophage NO release inhibition                     6.6 µM            Undetermined                                      CHN                            \[[@B190-marinedrugs-18-00005]\]

  Anti-inflammatory    *D. plectens* xenicane (**174**)/alga                   Terpenoid ^f^                  Macrophage NO release inhibition                     10 µM             Undetermined                                      CHN                            \[[@B191-marinedrugs-18-00005]\]

  Anti-inflammatory    comaparvin (**175**)/crinoid                            Polyketide ^d^                 Carrageenan-induced hyperalgesia inhibition          30 mg/kg \*       iNOS expression inhibition                        TWN                            \[[@B192-marinedrugs-18-00005]\]

  Anti-inflammatory    hirsutalins N and S (**176**, **177**)/ soft coral      Terpenoid ^f^                  Neutrophil elastase inhibition                       10 μM \*          Undetermined                                      TWN                            \[[@B193-marinedrugs-18-00005],[@B194-marinedrugs-18-00005]\]

  Anti-inflammatory    hirsutocospiro A (**178**)/soft coral                   Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               3.7--4.1 μM       Undetermined                                      TWN                            \[[@B195-marinedrugs-18-00005]\]

  Anti-inflammatory    isosinulaflexiolide K (**179**)/soft coral              Terpenoid ^f^                  Macrophage COX-2 and iNOS expression inhibition      \>10 μM \*        Undetermined                                      TWN                            \[[@B196-marinedrugs-18-00005]\]

  Anti-inflammatory    klyflaccisteroid F (**180**)/soft coral                 Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               0.34 μM           Undetermined                                      TWN                            \[[@B197-marinedrugs-18-00005]\]

  Anti-inflammatory    krempfielin N (**181**)/soft coral                      Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               \>10 μM \*        Undetermined                                      TWN                            \[[@B198-marinedrugs-18-00005]\]

  Anti-inflammatory    krempfielins Q and R (**182**, **183**)/soft coral      Terpenoid ^f^                  Neutrophil SOX and elastase inhibition               \>10 μM \*        Undetermined                                      TWN                            \[[@B199-marinedrugs-18-00005]\]

  Anti-inflammatory    methylfarnesylquinone (**184**)/alga                    Shikimate ^h^/Terpenoid ^f^    Neutrophil SOX and elastase inhibition               0.2--0.48 µg/mL   Undetermined                                      TWN                            \[[@B200-marinedrugs-18-00005]\]

  Anti-inflammatory    monanchosterol B (**185**)/sponge                       Terpenoid ^f^                  Macrophage IL-6 expression inhibition                5 µM              Undetermined                                      S. KOR                         \[[@B201-marinedrugs-18-00005]\]

  Anti-inflammatory    *P. nodosus* sterol (**186**)/starfish                  Terpenoid ^f^                  IL-12 and IL-6 inhibition                            1.3--3.1 µM       Undetermined                                      VNM, S. KOR                    \[[@B202-marinedrugs-18-00005]\]

  Anti-inflammatory    rhytidenone C (**187**)/fungus                          Polyketide ^d^                 Macrophage NO inhibition                             0.31 µM           Undetermined                                      THA                            \[[@B203-marinedrugs-18-00005]\]

  Anti-inflammatory    sarcocrassocolide E (**188**)/soft coral                Terpenoid ^f^                  Macrophage COX-2 and iNOS expression inhibition      \<10 μM \*        Undetermined                                      TWN                            \[[@B204-marinedrugs-18-00005]\]

  Anti-inflammatory    sinulacembranolide A (**189**)/octocoral                Terpenoid ^f^                  Macrophage iNOS expression inhibition                \<10 μM           Undetermined                                      TWN                            \[[@B205-marinedrugs-18-00005]\]

  Anti-inflammatory    thomimarine B (**190**)/fungus                          Terpenoid ^f^                  Macrophage NO inhibition                             \>10 μM           Undetermined                                      RUS, VNM                       \[[@B206-marinedrugs-18-00005]\]

  Anti-inflammatory    tortuosene A (**191**)/soft coral                       Terpenoid ^f^                  Neutrophil SOX inhibition                            7.3 μM            Undetermined                                      TWN                            \[[@B207-marinedrugs-18-00005]\]

  Immune system        grassypeptolide A (**192**)/cyanobacterium              Peptide ^g^                    IL-2 and T-cell proliferation inhibition             1 μM \*           Dipeptidyl peptidase 8 inhibition                 CHN, JPN, USA                  \[[@B208-marinedrugs-18-00005]\]

  Immune system        *F. reticulata* alkaloids (**193**)/sponge              Alkaloid ^g^                   IL-2 inhibition                                      5--50 µM \*       Undetermined                                      CHN, NLD                       \[[@B209-marinedrugs-18-00005]\]

  Immune system        luzonicoside A (**194**)/starfish                       Terpenoid ^f^                  Macrophage NO and ROS stimulation                    0.01--0.1 µM \*   Undetermined                                      RUS, VNM                       \[[@B210-marinedrugs-18-00005]\]

  Immune system        typicoside C1(**195**)/sea cucumber                     Terpenoid ^f^                  Macrophage ROS stimulation                           \<1 ng/mL \*      Undetermined                                      IND, RUS                       \[[@B211-marinedrugs-18-00005]\]

  **Nervous system**   aurone glycoside (**196**)/fungus                       Shikimate ^h^/Polyketide ^d^   Oxidative stress neuroprotection                     1 µM \*           Apoptosis inhibition                              CHN                            \[[@B212-marinedrugs-18-00005]\]

  Nervous system       azaspiracid-1 (**197**)/alga                            Polyketide ^d^/\               Peripherin-labelled neurite process                  15 nM \*          Peripherin isoform downregulation                 NOR                            \[[@B213-marinedrugs-18-00005]\]
                                                                               Alkaloid ^g^                                                                                                                                                                           

  Nervous system       caulerpine (**198**)/alga                               Alkaloid ^g^                   Antinociceptive activity                             40 mg/kg \*       Involves α2 and 5-HT~3~ receptors                 BRA                            \[[@B214-marinedrugs-18-00005]\]

  Nervous systema      6-bromohypaphorine (**199**)/sea slug                   Alkaloid ^g^                   Human α7 nAChR agonist                               23 µM             Rise \[Ca^2+^ \]i                                 RUS                            \[[@B215-marinedrugs-18-00005]\]

  Nervous system       piscidin (**200**)/fish                                 Peptide ^g^                    Antinociceptive activity                             20 µg/rat \*      Phosphor-mTOR inhibition                          TWN                            \[[@B216-marinedrugs-18-00005]\]

  Nervous system       *C. marmoreus* conotoxin Mr1.7 (**201**)/cone snail     Peptide ^g^                    Ach-evoked membrane current inhibition               53.1 nM           A3β2 nAChR inhibition                             CHN                            \[[@B217-marinedrugs-18-00005]\]

  Nervous system       *C. litteratus* conotoxin lt16a (**202**)/cone snail    Peptide ^g^                    Neuronal Na^+^ current inhibition                    1 µM \*           Undetermined                                      CHN                            \[[@B218-marinedrugs-18-00005]\]

  Nervous system       *C. vitulinus* peptide (**203**)/ cone snail            Peptide ^g^                    Neuronal BK channel inhibition                       8.5 µM            Electrostatic interaction with β4 subunits        CHN, USA                       \[[@B219-marinedrugs-18-00005]\]

  Nervous system       echinochrome A (**204**)/sea urchin                     Polyketide ^d^                 Acetylcholinesterase inhibition and NO scavenging    16.4 µM           Irreversible and uncompetitive inhibition         S. KOR, RUS                    \[[@B220-marinedrugs-18-00005]\]

  Nervous system       ganglioside LLG-3 (**205**)/starfish                    Glycolipid                     Neuritogenesis stimulation in vitro                  1 nM \*           MAPK signaling stimulation                        JPN                            \[[@B221-marinedrugs-18-00005]\]

  Nervous system       heteronemin (**206**)/sponge                            Terpenoid ^f^                  TDP-43 binding to DNA inhibition                     10.1 nM           Promoted aggregation of insoluble TDP-43          ITA                            \[[@B222-marinedrugs-18-00005]\]

  Nervous system       pinnatoxin A (**207**)/mollusc                          Polyketide ^d^/\               Muscle and neuronal nAChRs receptor inhibition       0.086--47.5 nM    EF-ketal ring confers nAChR subtype specificity   FRA, USA                       \[[@B223-marinedrugs-18-00005]\]
                                                                               Alkaloid ^g^                                                                                                                                                                           

  Nervous tissue       PhcrTx1 (**208**)/sea anemone                           Peptide ^g^                    ASIC inhibition                                      100 nM            Lower potency on Kv channels                      BEL, BRA, CUB, DEU, ESP, MEX   \[[@B224-marinedrugs-18-00005]\]

  Nervous tissue       phlorofucofuroeckol-A (**10**)/alga                     Polyketide ^d^                 Butyrylcholinesterase inhibition                     0.95 µM           β-secretase inhibition                            S. KOR                         \[[@B225-marinedrugs-18-00005]\]

  Nervous tissue       *S. auritum* ceramide (**209**)/soft coral              Polyketide ^d^                 Anxiolytic and CNS depressing activity in vivo       1 mg/kg \*\*      GABA(A) receptor modulation                       EGY, USA                       \[[@B226-marinedrugs-18-00005]\]

  Nervous system       spirolide C (**210**)/dinoflagellate                    Polyketide ^d^/\               nAChR inhibition                                     1.5--3 nM \*      Muscle and neuronal -type nAChR inhibition        FRA                            \[[@B227-marinedrugs-18-00005]\]
                                                                               Alkaloid ^g^                                                                                                                                                                           

  Nervous system       zonarol (**211**)/alga                                  Meroterpenoid ^f^              Glutamate toxicity inhibition in vitro               0.22 µM           Nrf2/ARE pathway activation                       JPN, USA                       \[[@B228-marinedrugs-18-00005]\]

  Nervous system       aplysinellamide-1 (**212**)/sponge                      Alkaloid ^g^                   ApoE secretion modulation                            30 µM \*          Undetermined                                      AUS, CAN                       \[[@B229-marinedrugs-18-00005]\]

  Nervous system       *A. terreus* lactones (**120**, **121**)/fungus         Polyketide ^d^                 acetylcholinesterase inhibition                      4.2 µM            Undetermined                                      CHN                            \[[@B115-marinedrugs-18-00005]\]

  Nervous system       *C. araneosus* ar3j conotoxin (**213**)/cone snail      Peptide ^g^                    Sleep induction                                      2 nM \*           Undetermined                                      IND                            \[[@B230-marinedrugs-18-00005]\]

  Nervous system       *D. cejpii* steroid (**214**)/fungus                    Terpenoid ^f^                  Amyloid β-42 production inhibition                   10 µM \*          Undetermined                                      DEU, FRA                       \[[@B231-marinedrugs-18-00005]\]

  Nervous system       genuanine (**215**)/cone snail                          Alkaloid ^g^                   Paralysis in vivo                                    40 nM \*          Undetermined                                      PRT, USA                       \[[@B232-marinedrugs-18-00005]\]

  Nervous system       homoaerothionin (**216**)/sponge                        Alkaloid ^g^                   acetylcholinesterase inhibition                      2.9--6.2 µM       Undetermined                                      THA                            \[[@B233-marinedrugs-18-00005]\]

  Nervous system       mooreamide A (**217**)/bacterium                        Polyketide ^d^                 CB~1~ binding                                        0.47 µM \*\*      Undetermined                                      ITA, PNG, USA                  \[[@B234-marinedrugs-18-00005]\]

  Nervous system       *S. spinosulus* hydroquinone (**218**)/sponge           Shikimate ^h^/Polyketide ^d^   Enhance glutamate and ACh release                    10 µM \*          Undetermined                                      ITA                            \[[@B235-marinedrugs-18-00005]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^**Organism:***Kingdom Animalia*: fish (Phylum Chordata); bryozoan; coral and sea anemone (Phylum Cnidaria); crinoid, sea urchin, starfish (Phylum Echinodermata); cone snail, sea slug (Phylum Mollusca); sponge (Phylum Porifera); *Kingdom Fungi*: fungus; *Kingdom Plantae:* alga; *Kingdom Monera*: bacterium; *Kingdom Protozoa*: dinoflagellates; ^b^ **IC~50~**: concentration of a compound required for 50% inhibition, \*: apparent IC~50~, \*\*: in vivo study; \*\*: *K*~i~: concentration needed to reduce the activity of an enzyme by half; ^c^ **MMOA:** molecular mechanism of action; ^d^ **Country:** AUS: Australia; BEL: Belgium; BRA: Brazil; CAN: Canada; CHN: China; CUB: Cuba; DEU: Germany; DNK: Denmark; EGY: Egypt; ESP: Spain; FIN, Finland; FRA: France; IDN: Indonesia; IND, India; ITA: Italy; JPN: Japan; LKA: Sri Lanka; MEX: Mexico; MYS: Malaysia; NLD: Netherlands; NOR: Norway; PNG: Papua New Guinea; PRT: Portugal; RUS: Russian Federation; S. KOR: South Korea; THA: Thailand; TWN: Taiwan; VNM: Vietnam; **Chemistry:** ^e^ Polyketide; ^f^ Terpene; ^g^ Nitrogen-containing compound; ^h^ Shikimate. **Abbreviations:** Ach: acetylcholine; ApoE: apolipoprotein E; ASIC: acid-sensing sodium ion channel; CAT: catalase; CB~1~: cannabinoid receptor 1; CNS: central nervous system; COX: cyclooxygenase; HO-1: heme oxygenase-1; ICAM: intercellular adhesion molecule-1; IL: interleukin; iNOS: inducible nitric oxide synthase; Kv current: voltage-gated K+ current; MAPK: mitogen-activated protein kinase pathway; MDC/CCL22: macrophage-derived chemokine, C--C motif chemokine 22; nAChR: nicotinic acetylcholine receptor; NA: not available; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NO: nitric oxide; nAChR: nicotinic acetylcholine receptor; Nrf2-ARE: nuclear transcription factor E2-related factor antioxidant response element; PTP1B: tyrosine protein; phosphatase 1B; ROS: reactive oxygen species; SOD: superoxide dismutase; SOX: superoxide; STAT1: signal transducer and activator of transcription1; TDP-43: trans-activation response DNA-binding protein of 43 kDa.
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###### 

Marine pharmacology in 2014--2015: marine compounds with miscellaneous mechanisms of action.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound/Organism ^a^                                              Chemistry        Pharmacological Activity ^i^                                   IC~50~ ^b^          MMOA ^c^                                                 Country ^d^          References
  ------------------------------------------------------------------ ---------------- -------------------------------------------------------------- ------------------- -------------------------------------------------------- -------------------- ---------------------------------------------------------------
  AdE-1 (**219**)/sea anemone                                        Peptide ^g^      Cardiomyocyte action potential modulation                      2 nM \*             Na^+^ and K^+^ current increase                          ISR                  \[[@B236-marinedrugs-18-00005]\]

  aaptamine (**220**)/sponge                                         Alkaloid ^g^     ROS inhibition                                                 10 μM \*            Cytokine inhibition                                      S. KOR               \[[@B237-marinedrugs-18-00005]\]

  amphirionin-4 (**221**)/dinoflagellate                             Polyketide ^e^   Bone marrow stromal cells proliferation stimulation            \<0.1 ng/mL         Cytoskeleton protein synthesis                           JPN                  \[[@B238-marinedrugs-18-00005]\]

  astaxanthin (**145**)/alga                                         Terpenoid ^f^    Leydig cell steroidogenesis protection                         10 µg/mL \*         ROS scavenging                                           TWN                  \[[@B239-marinedrugs-18-00005]\]

  bastadins 6 and 16 (**222**, **223**)/sponge                       Alkaloid ^g^     Foam cell formation inhibition                                 5 μM \*             ACAT inhibition                                          JPN                  \[[@B240-marinedrugs-18-00005]\]

  6,6-bieckol (**224**)/alga                                         Polyketide ^e^   Adipocyte differentiation inhibition                           50 µg/mL \*         Adipogenesis inhibition                                  S. KOR               \[[@B241-marinedrugs-18-00005]\]

  (-)-chlorizidine A (**225**)/bacterium                             Alkaloid ^g^     Increase G~1~ cell cycle phase                                 2 μM \*             GAPDH and hENO1 binding                                  BRA, USA             \[[@B242-marinedrugs-18-00005]\]

  dihydroaustrasulfone alcohol (**226**)/soft coral                  Polyketide ^e^   PDGF-induced HASMC proliferation and angiogenesis inhibition   10 μM \*            DNA synthesis and VEGF signaling inhibition              TWN                  \[[@B243-marinedrugs-18-00005],[@B244-marinedrugs-18-00005]\]

  DPHC (**227**)/alga                                                Terpenoid ^f^    UVB radiation-induced DNA damage protection                    20 μM \*            Nucleotide excision repair system induction              S. KOR               \[[@B245-marinedrugs-18-00005]\]

  echinochrome A (**204**)/sea urchin                                Alkaloid ^g^     Cardiac contractility inhibition                               3 μM \*             SERCA2A inhibition                                       BEL, S. KOR, RUS     \[[@B246-marinedrugs-18-00005]\]

  echinochrome A (**204**)/sea urchin                                Alkaloid ^g^     Increased mitochondria biogenesis and function                 5 μM \*             Mitochondrial biogenesis genes upregulation              S. KOR, RUS          \[[@B247-marinedrugs-18-00005]\]

  eckol (**228**)/alga                                               Polyketide ^e^   ROS suppression in cells                                       10 μM \*            Increased HO-1 expression                                S. KOR               \[[@B248-marinedrugs-18-00005]\]

  emindole SB (**229**)/fungus                                       Terpenoid ^f^    Nonselective CB~1~/CB~2~ antagonist                            2.2--7.0 μM \*\*    Undetermined                                             CHE, DEU             \[[@B249-marinedrugs-18-00005]\]

  farnesylquinone (**230**)/bacterium                                Polyketide ^e^   Decreased lipid accumulation                                   1 μM \*             Increased PPARα activity                                 CHN, DEU             \[[@B250-marinedrugs-18-00005]\]

  FGFC1 (**231**)/fungus                                             Alkaloid ^g^     Thrombolysis induction in vivo                                 5 mg/kg \*          Fibrin hydrolysis induction\                             CHN                  \[[@B251-marinedrugs-18-00005]\]
                                                                                                                                                                         in vitro                                                                      

  formosusin A (**232**)/fungus                                      Alkaloid ^g^     Mammalian DNA polymerase β inhibition                          35.6 μM             Competitive and non-competitive inhibition               JPN                  \[[@B252-marinedrugs-18-00005]\]

  fucodiphlorethol (**233**)/alga                                    Polyketide ^e^   ROS inhibition                                                 10 μM \*            Decreased mitochondrial loss, and caspase-9 expression   S. KOR               \[[@B253-marinedrugs-18-00005]\]

  gallic acid (**234**)/alga                                         Shikimate ^h^    NO-dependent vasorelaxant effect                               12.5 µg/mL          Phospho-eNOS increase                                    S. KOR               \[[@B254-marinedrugs-18-00005]\]

  gallinamide A (**235**)/bacterium                                  Peptide ^f^      Human cathepsin L inhibition                                   5 nM                Covalent inhibition                                      USA                  \[[@B255-marinedrugs-18-00005]\]

  girolline (**236**)/sponge                                         Alkaloid ^g^     TLR 5 inhibition                                               2 µg/mL             IL-8 and IL-6 inhibition                                 CAN, NLD, USA        \[[@B256-marinedrugs-18-00005]\]

  gracilins A, H, L (**237--239**)/sponge                            Terpenoid ^f^    mPTP opening inhibition                                        1 μM \*             Binding to CypD                                          EGY, ESP, GBR        \[[@B257-marinedrugs-18-00005]\]

  *H. crispa* polypeptides (**240**, **241**)/sea anemone            Peptide ^f^      Macrophage TNF-α, IL-6, and proIL-1β inhibition                                    Trypsin and α-chemotrypsin inhibition                    RUS, TWN             \[[@B258-marinedrugs-18-00005]\]

  *Hyrtios* sp. sesterterpene (**242**)/sponge                       Terpenoid ^f^    TDP-43 inhibition                                              0.4 nM              TDP-43 to DNA binding inhibition                         ITA, PYF             \[[@B259-marinedrugs-18-00005]\]

  irciniastatin A (**243**)/sponge                                   Polyketide ^e^   TNF-α receptor 1 ectodomain shedding                           10 nM \*            ERK activation induced                                   JPN                  \[[@B260-marinedrugs-18-00005]\]

  iejimalide C (**244**)/ascidian                                    Polyketide ^e^   V-ATPase inhibitor                                             0.12 μM             Bafilomycin site binding                                 JPN                  \[[@B261-marinedrugs-18-00005]\]

  *Laurencia* sp. indole (**245**)/alga                              Alkaloid ^g^     Aryl hydrocarbon receptor agonist                              10 μM \*            DNA binding stimulation and CYP1A1 induction             JPN, USA             \[[@B262-marinedrugs-18-00005]\]

  neopetroside A (**246**)/sponge                                    Alkaloid ^g^     Cardiomyocyte mitochondrial upregulation                       10 µM \*            Increased ATP levels and O~2~ consumption                RUS, S. KOR          \[[@B263-marinedrugs-18-00005]\]

  Phlorofucofuroeckol-A (**10**)/alga                                Polyketide ^e^   Lipid accumulation inhibition                                  18 µM               Decreased PPARγ expression                               S. KOR               \[[@B264-marinedrugs-18-00005]\]

  polytheonamide B (**247**)/sponge                                  Peptide ^g^      One-ion pore channel permeation determined                     NA                  Two ion binding sites defined, but second ion excluded   JPN                  \[[@B265-marinedrugs-18-00005]\]

  siphonaxanthin (**248**)/alga                                      Terpenoid ^f^    Adipogenesis inhibition                                        5 µM                Transcription factor inhibition                          JPN                  \[[@B266-marinedrugs-18-00005]\]

  spiromastixones J and L (**57**, **249**)/fungus                   Polyketide ^e^   Cholesterol uptake inhibition                                  10 μM \*            PPARγ upregulation                                       CHN                  \[[@B267-marinedrugs-18-00005]\]

  thalassospiramide C (**250**)/bacterium                            Peptide ^g^      HCAN1 inhibition                                               3.4 nM              Binding to Cys115 residue                                CHN, USA             \[[@B268-marinedrugs-18-00005]\]

  xyloketal B (**251**)/fungus                                       Polyketide ^e^   Atherosclerotic plaque attenuation                             14 mg/kg \*\*\*     Increased eNOS activity                                  CAN, CHN             \[[@B269-marinedrugs-18-00005]\]

  xyloketal B (**251**)/fungus                                       Polyketide ^e^   P450 3a activity and expression regulation                     14 mg/kg \*\*\*     Active site binding determined by docking studies        CHN, USA             \[[@B270-marinedrugs-18-00005]\]

  *X. testudinaria* lipid (**252**)/sponge                           Polyketide ^e^   Pancreatic lipase inhibition                                   3.11 μM             Triglyceride level decrease in vivo                      CHN, ITA             \[[@B271-marinedrugs-18-00005]\]

  acuminolide A (**253**)/dinoflagellate                             Polyketide ^e^   Stimulation of actomyosin ATPase                               1 μM \*             Undetermined                                             S. KOR               \[[@B272-marinedrugs-18-00005]\]

  ahpatinin Ac (**254**)/bacterium                                   Peptide ^g^      Pepsin inhibition                                              11 nM               Undetermined                                             JPN                  \[[@B273-marinedrugs-18-00005]\]

  alternariol derivatives (**255--257**)/sponge                      Shikimate ^h^    HCV protease inhibition                                        12--52 µg/mL        Undetermined                                             EGY, SAU             \[[@B136-marinedrugs-18-00005]\]

  apliamide D (**258**)/ascidian                                     Peptide ^g^      Na^+^/K^+^-ATPase inhibition                                   3.2 μM              Undetermined                                             S. KOR               \[[@B274-marinedrugs-18-00005]\]

  austalides 4 and 9 (**259**, **260**)/fungus                       Terpenoid ^f^    *Endo*-1,3-*β*-D-glucanase inhibition                          0.01 μM             Undetermined                                             RUS                  \[[@B275-marinedrugs-18-00005]\]

  axinelline A (**261**)/bacterium                                   Alkaloid ^g^     COX-2 inhibition                                               2.8 μM              Undetermined                                             CHN                  \[[@B276-marinedrugs-18-00005]\]

  brevisulcatic acid-4 (**262**)/dinoflagellate                      Polyketide ^e^   Activation of sodium channels                                  20 ng/mL            Undetermined                                             JPN, NZL             \[[@B277-marinedrugs-18-00005]\]

  4′,5′-dehydrodiodictyonema (**263**)/alga                          Terpenoid ^f^    PTP1B inhibition                                               2.3 μM              Undetermined                                             CHN                  \[[@B278-marinedrugs-18-00005]\]

  *D. metachromia* sesquiterpenes (**264--266**)/sponge              Terpenoid ^f^    Multiple kinases inhibition                                    0.97--4.8 μM        Undetermined                                             CHN, NLD, DEU        \[[@B279-marinedrugs-18-00005]\]

  didemnaketals D and E (**267**, **268**)/ascidian                  Terpenoid ^f^    Multiple kinases inhibition                                    10 μg/mL \*         Undetermined                                             EGY                  \[[@B280-marinedrugs-18-00005]\]

  dysiquinol D (**269**)/sponge                                      Terpenoid ^f^    NF-κB inhibition                                               0.81 μM             Undetermined                                             AUS, CHN             \[[@B281-marinedrugs-18-00005]\]

  fucoxanthin (**134**)/alga                                         Terpenoid ^f^    Hydroxyl radical-scavenging                                    10 μg/mL \*         Undetermined                                             CHN                  \[[@B282-marinedrugs-18-00005]\]

  halenaquinol sulfate (**270**)/sponge                              Polyketide ^e^   CDK9 and DYRK1A inhibition                                     0.5--0.61 μM        Undetermined                                             FRA, NZL             \[[@B283-marinedrugs-18-00005]\]

  1-hydroxyethylhalenaquinone (**271**)/sponge                       Polyketide ^e^   Proteasome-chymotrypsin-like activity inhibition               0.19 μM             Undetermined                                             IDN, JPN, NLD        \[[@B284-marinedrugs-18-00005]\]

  hymenialdisine derivatives (**272--274**)/sponge                   Alkaloid ^g^     P*f*GSK-3 inhibition                                           0.07--0.2 μM        Undetermined                                             DEU, EGY, FRA, NLD   \[[@B285-marinedrugs-18-00005]\]

  hymenialdisine (**275**)/sponge                                    Alkaloid ^g^     CK1, CDK5, GSK3β inhibition                                    0.03--0.16 μM       Undetermined                                             AUS                  \[[@B286-marinedrugs-18-00005]\]

  hyattellactone A (**276**)/sponge                                  Terpenoid ^f^    PTP1B inhibition                                               7.45 μM             Undetermined                                             IDN, JPN             \[[@B287-marinedrugs-18-00005]\]

  *H. lachne* sesterterpenoid (**277**)/sponge                       Terpenoid ^f^    PTP1B inhibition                                               5.2 μM              Undetermined                                             CHN                  \[[@B288-marinedrugs-18-00005]\]

  ianthelliformisamines A--C (**278**, **7**, **8**)/ sponge         Alkaloid ^g^     Carbonic anhydrase inhibition                                  0.2--0.85 μM \*\*   Undetermined                                             AUS, ITA             \[[@B289-marinedrugs-18-00005]\]

  incisterols A5 and A6 (**279**, **280**)/sponge                    Terpenoid ^f^    PXR agonists                                                   10 μM \*            Undetermined                                             ITA                  \[[@B290-marinedrugs-18-00005]\]

  *L. crassum* cembranoid (**281**)/soft coral                       Terpenoid ^f^    PPAR transcription activation                                  2.07 μM             Undetermined                                             VNM                  \[[@B291-marinedrugs-18-00005]\]

  *L. okamurai* terpenoid (**282**)/alga                             Terpenoid ^f^    PTP1B inhibition                                               4.9 μg/mL           Undetermined                                             CHN                  \[[@B292-marinedrugs-18-00005]\]

  malonganenone L (**283**)/sea whip                                 Alkaloid ^g^     PDE4D inhibition                                               8.5 μM              Undetermined                                             CHN                  \[[@B293-marinedrugs-18-00005]\]

  punctaporonin K (**284**)/fungus                                   Terpenoid ^f^    Lipid-lowering effect                                          10 μM \*            Undetermined                                             CHN, DEU             \[[@B294-marinedrugs-18-00005]\]

  psychrophilin G (**285**)/fungus                                   Peptide ^g^      Lipid-lowering effect                                          10 μM \*            Undetermined                                             CHN                  \[[@B295-marinedrugs-18-00005]\]

  racemosin (**286**)/alga                                           Alkaloid ^g^     PTP1B inhibition                                               5.9 µM              Undetermined                                             CHN                  \[[@B296-marinedrugs-18-00005]\]

  sarcoehrendin B (**287**)/soft coral                               Polyketide ^e^   PDE4 inhibition                                                3.7 µM              Undetermined                                             CHN                  \[[@B297-marinedrugs-18-00005]\]

  sarsolilide A (**288**)/soft coral                                 Terpenoid ^f^    PTP1B inhibition                                               6.8 µM              Undetermined                                             CHN, HUN             \[[@B298-marinedrugs-18-00005]\]

  *Stachybotry* sp. xanthone (**289**)/fungus                        Polyketide ^e^   COX-2 inhibition                                               8.9 µM              Undetermined                                             CHN                  \[[@B299-marinedrugs-18-00005]\]

  *S. thunbergii* alkapolyene (**290**)/alga                         Polyketide ^e^   Soybean LOX inhibition                                         5 µM                Undetermined                                             JPN, S. KOR          \[[@B300-marinedrugs-18-00005]\]

  shinorine (**291**)/alga                                           Alkaloid ^g^     *C. histolyticum* collagenase inhibition                       104 µM              Undetermined                                             AUT                  \[[@B301-marinedrugs-18-00005]\]

  sinularone D (**292**)/soft coral                                  Polyketide ^e^   NF-κB inhibition                                               10 μg/mL \*         Undetermined                                             CHN                  \[[@B302-marinedrugs-18-00005]\]

  *N*-(2-benzenepropanoic acid) stachybotrylactam (**293**)/fungus   Alkaloid ^g^     Triglyceride and cholesterol inhibition                        10 μM \*            Undetermined                                             CHN, DEU             \[[@B303-marinedrugs-18-00005]\]

  strongylophorine-13/-14 (**294**)/sponge                           Terpenoid ^f^    Hu proteasome 20S inhibition                                   2.1 μM              Undetermined                                             JPN                  \[[@B304-marinedrugs-18-00005]\]

  swinhoeisterol A (**295**)/sponge                                  Terpenoid ^f^    (h)P300 acetyltransferase inhibition                           2.7 μM              Undetermined                                             ITA, CHN, USA        \[[@B305-marinedrugs-18-00005]\]

  thunberol (**296**)/alga                                           Terpenoid ^f^    PTP1B inhibition                                               2.24 μg/mL          Undetermined                                             CHN                  \[[@B306-marinedrugs-18-00005]\]

  xestosaprol O (**297**)/sponge                                     Terpenoid ^f^    IDO1 inhibition                                                4 μM                Undetermined                                             CAN, NLD             \[[@B307-marinedrugs-18-00005]\]

  urupocidin A (**298**)/sponge                                      Alkaloid ^g^     iNOS expression induction                                      10 μM \*            Undetermined                                             RUS, TWN             \[[@B308-marinedrugs-18-00005]\]

  variabine B (**299**)/sponge                                       Alkaloid ^g^     Proteasome-chymotrypsin-like activity inhibition               4 µg/mL             Undetermined                                             IDN, JPN, NLD        \[[@B309-marinedrugs-18-00005]\]

  yoshinone A (**300**)/cyanobacterium                               Polyketide ^e^   Triglyceride inhibition                                        0.4 μM              Undetermined                                             JPN                  \[[@B310-marinedrugs-18-00005]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^**Organism**, *Kingdom Animalia*: ascidian (Phylum Chordata), soft corals, sea whips, and sea anemone (Phylum Cnidaria), dinoflagellates (Phylum Dinoflagellata), sea urchin (Phylum Echinodermata), sponge (Phylum Porifera); *Kingdom Fungi*: fungus; *Kingdom Plantae:* alga; *Kingdom Monera*: bacterium; ^b^ **IC~50~**: concentration of a compound required for 50% inhibition in vitro; \*: estimated IC~50~; \*\*: Ki; \*\*\* in vivo study; ^c^ **MMOA**: molecular mechanism of action; ^d^ **Country:** AUS: Australia; AUT: Austria; BEL: Belgium; BRA: Brazil; CAN: Canada; CHE: Switzerland; CHN: China; DEU: Germany; EGY: Egypt; FRA: France; ESP: Spain; GBR: United Kingdom; HUN: Hungary; IDN: Indonesia; ISR: Israel; ITA: Italy; JPN: Japan; NLD: The Netherlands; NZL: New Zealand; PYF: French Polynesia; RUS: Russian Federation; SAU: Saudi Arabia; S. KOR: South Korea; TWN: Taiwan; VNM: Vietnam; **Chemistry:** ^e^ Polyketide; ^f^ Terpene; ^g^ Nitrogen-containing compound; ^h^ shikimate; **Abbreviations:** ACAT: acyl-CoA:cholesterol acyl-transferase; CB: cannabinoid; CDK: cyclin-dependent kinase; COX-2: cyclooxygenase 2; CK1: casein kinase 1; CypD: cyclophilin D; DDYRK: dual-specificity, tyrosine phosphorylation regulated kinase; DPHC: diphlorethohydroxycarmalol; eNOS: endothelial nitric oxide synthase; ERK: extracellular signal-regulated kinase; GAPDH: D-glyceraldehyde-3-phosphate dehydrogenase; GSK3β: glycogen synthase kinase 3; HASMC: human aortic smooth muscle cells; HCAN1: human calpain 1 protease; HCV: hepatitis C virus; hENO1: human alpha-enolase; hu: human; HO-1: hemeoxygenase-1; IDO1: indoleamine 2, 3 dioxygenase; IL: interleukin; iNOS: inducible nitric oxide synthase; LOX: lipoxygenase; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NO: nitric oxide; mPTP: mitochondrial permeability transition pore; PDGF: platelet-derived growth factor; PDE4: phosphodiesterase 4; PPAR: peroxisome proliferator-activated receptor; PTP1B: protein tyrosine phosphatase 1B; PXR: pregnane-X-receptor; ROS: reactive oxygen species; SERCA2A: SR Ca^2+^ ATPase 2A; TLR5: Toll-like receptor 5; TDP-43: trans-activation response DNA-binding protein of 43 kDa; UVB: ultraviolet B; V-ATPase: vacuolar-type H^+^-ATPase; VEGF: vascular endothelial growth factor.
